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ABSTRACT
Engineering nucleases is important to the advancement of genetic engineering
and gene therapy approaches. Engineering requires a knowledge of which residues
are contributing to each function of the nuclease. The residues which contribute to
cleavage specificity of the I-TevI nuclease domain (ND) are unknown. I suspect that
some of these contributions derive from the ND, thus my null hypothesis is that
mutation of the ND will not alter the substrates this enzyme can cut. I have
mutagenised the I-TevI nuclease domain and using directed evolution I have isolated
mutations which were characterised in vivo and in vitro. These mutations permit
cleavage of otherwise cleavage resistant substrates, indicating that the ND does
contribute to cleavage specificity. Mutations which provided the greatest increase in
activity against cleavage resistant substrates (K26R, T95S, and Q158R) were
combined into a single relaxed specificity nuclease domain which exhibits 1.2-5-fold
improved cleavage of resistant substrates.
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Chapter 1

INTRODUCTION

Engineering nucleases is important for the advancement of genome editing, a
core component of genetic engineering and gene therapy approaches1-3. Optimally, a
system would be developed such that a nuclease could be immediately identified and
produced to edit any gene. Such an enzyme would have to specifically target an
extended DNA sequence to ensure editing at a single unique site in a genomic context.
This level of specificity requires extensive protein-DNA contacts over a long stretch of
DNA. Homing endonucleases (HEs) are a class of nucleases that recognise DNA
sequences that are 12-40 bp in length, a characteristic that allows them to potentially
effect a genetic change at a single position in a host organism's genome 4. HEs effect
contacts over these lengthy DNA sequences through the combination of multiple DNA
binding 'modules' that each contribute to the relative degree of cleavage that a nuclease
can effect on each of a related set of substrates, hereafter called its cleavage profile.
These modules can be recombined to generate libraries of engineered nucleases, each
with a unique cleavage profile. Such libraries could represent a source of versatile
genome editing tools.
I-TevI is a HE comprised of three modules: an N-Terminal nuclease domain
(ND), a C-terminal DNA binding domain (DBD), and a linker region that connects the
two domains5. The I-TevI ND has been recombined with other DBDs to generate
chimaeric nucleases that combine the cleavage profile of the chosen DBD with that of
the I-TevI ND6. The range of cleavage profiles possible from chimaeric nucleases like
these could be further extended by rationally designing a library of engineered I-TevI
NDs with distinct cleavage profiles. Rational design of a nuclease requires that the
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amino acids which contribute to DNA sequence readout are known; this is not the case
for the I-TevI ND.
In this thesis I describe how I used directed evolution to screen for mutant ITevI NDs that were able to cleave otherwise poorly cleaved DNA substrates. Further, I
describe the process by which I isolated and characterised the impact of mutations that
were identified from the screens on the I-TevI ND cleavage profile in vivo and in vitro.
Subsequently, I relate the identified mutations and their impacts on the I-TevI ND
cleavage profile to previously identified mutations in the I-TevI ND and to other
attempts to develop nucleases with altered cleavage profiles. Finally, I give an insight
into how these mutant NDs will be used to better understand the source of its cleavage
profile towards the ultimate goal of rationally designing a library of I-TevI NDs with
unique cleavage profiles for use in genome editing.

1.1

Genome Editing
Genome editing is a technique in which a specific genetic locus of an organism's

genome is targeted for removal, replacement, or insertion of new genetic material. The
editing process is facilitated by nucleases that recognise the chosen target locus, and
create a nick or double-strand break (DSB) within the locus. The breakage of a DNA
strand then elicits the DNA repair pathways to mend the break, either by
nonhomologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), or
homology-directed repair (HDR), which can be utilised to effect genetic changes. The
variety and versatility of genome editing tools has seen a tremendous amount of growth
in the past decade. These genome editing tools are typically exploited by one of two
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related fields: genetic engineering (§ 1.1.2) or gene therapy (§ 1.1.3).

1.1.1 Mechanisms of Genome Editing with Nucleases
Genome editing with nucleases is achieved by eliciting DNA repair pathways,
each of which offer unique opportunities for editing (Figure 1.1) 7. NHEJ, and MMEJ
can remove nucleotides surrounding the site of damage and thus can be used to create a
deletion or gene knock-out; HDR uses a template to effect reconstruction of the broken
strand, and thus if a donor template is provided, the owriginal sequence surrounding the
break can be replaced with a DNA sequence from the donor template.

1.1.2 Genome Editing in Genetic Engineering
Genetic engineering is the artificial genetic modification of an organism in order
to make it more useful in a particular context. Genetic engineering is used extensively in
the field of biomedical research to create genetically modified organisms that provide
model systems for human diseases8. Other genetically modified organisms created using
genetic engineering include knock-out and knock-in mice, which express an aberrant
phenotype that facilitates an understanding of gene function9. Genetic engineering can
also be used to create gene-fusions that encode a protein of interest joined with a
reporting element such as green fluorescent protein which allow for tracking and
localisation of said protein in a single-cell or whole-organism context10,11.
Genetic engineering is also used in the agricultural industry, which has benefitted
tremendously from the development of transgenic plants. Thus there is a great interest in
engineering genome editing tools to aid in further developments. To this end the HE
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Figure 1.1. Mechanisms of DNA DSB repair provide opportunities for
genome editing. The three cannonical modes of DNA DSB repair are shown
above. NHEJ and MMEJ both begin with resection of the 5' ends created by the
DSB, but their mechanisms diverge thereafter. In NHEJ, digestion of the 3'
overhangs created by resection creates blunt ends, which are ligated together. In
MMEJ, regions of microhomology between the 3' overhangs are brought
together, excess 3' ends are removed, and missing nucleotides are filled in
adjacent to the microhomologous region. HDR uses a donor template with
homologous regions on both sides of the DSB. The region adjacent to the DSB
is replaced by replicating the donor template.
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I-CreI has been re-engineered to generate transgenic varieties of maize by effecting
insertions and deletions at a defined site within immature embryos 12. Further, multigene
plant transformation vectors have been developed that employ a cloning system
composed of zinc-finger (ZF) nucleases (ZFNs) and HEs 13, and plant viral vectors have
been used to deliver endonuclease genes14.
The medical and pharmaceutical industries have benefited from genetically
engineered organisms that produce therapeutic proteins, such as human insulin and
human growth hormone15. Genetic engineering is also a promising avenue of research
for the field of renewable energy. Genetically engineered photosynthetic algae present
the unique opportunity to harness solar energy and convert it directly into biofuels 16, or
value-added products17. One interesting offshoot of genetic engineering is its impact on
computer technology. Bacterial chromosomes were harnessed to generate a DNA-based
retrievable data storage unit18,19 and to effect digital control of gene expression, which
are first steps towards a biological computer20.
Genetic engineering is also being investigated for its potentially transformative
effect on population genetics and allelic frequencies. In one application, potentially
disease carrying mosquitoes of the species Anopheles gambia were engineered for
reduced fertility by targeting their genome with a synthetic genetic element containing
the HE I-SceI21,22. Similar results were observed using the I-PpoI HE gene in male
mosquitoes23. Related studies of the propagation of malaria by mosquitoes predict that
transmission of a HE gene in this manner would reduce the incidence and spread of
malaria24.
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1.1.3 Genome Editing in Gene Therapy
Gene therapy is in situ or ex vivo DNA correction or manipulation to restore a
healthy state to a diseased organism. Such corrections could ameliorate countless
hereditary disorders, or eliminate core components of a provirus. The promise of much
needed medical advancements has spurred countless attempts to apply genome editing
techniques to human disease. The more promising applications involve monogenic
diseases that can be treated ex vivo, such as blood disorders, skin ailments, and
immunodeficiencies25. Notably, a successful proof of concept treatment of the
monogenic immunodeficiency, ADA-SCID was demonstrated using using viral
vectors26. However, off-target gene integration led to leukemia in five patients, and one
patient's death. Thus, engineered genome editing tools with more precise targeting are
needed27.
Some preliminary success in using genome editing tools for gene therapy have
been achieved using engineered recombinases. Recombinases are a class of enzymes
that are capable of translocating genetic material between a DNA vector and a genome
(see §1.2.1). This ability to move genetic material has been exploited in mice to develop
a number of potential treatments for diseases such as hemophilia28, muscular
dystrophy29, Junctional epidermolysis bullosa30, peripheral vascular disease31, and
rheumatoid arthritis32. Some success has also been had with recombinases in human
cells, such as the genetic correction of dystrophic epidermolysis bullosa in primary
patient cells33, and the reprogramming of somatic cells to pluripotency34, 35.
A lot of work has gone into developing gene therapy approaches for treating HIV
infection. In one such study designer endonucleases were coupled in trans with DNA
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end-processing enzymes to bias DNA repair towards using HDR 36. In one such
application a 3′ repair exonuclease, Trex2, was overexpressed along with ZFNs,
transcription activator like effector nucleases (TALENs), or an engineered I-CreI
LAGLIDADG HE (LHE). The result was an improved yield of targeted gene disruption
in several different cell lines. In particular, the I-CreI based approach effected a sevenfold increase in gene disruption of the endogenous HIV coreceptor CCR5 36.
Furthermore, the ZFN-based approach is now in clinical trials 37. Other approaches have
sought to eliminate the virus in its proviral phase. The LHE I-AniI has been shown to
cure cells of latent HIV infection by mutagenising key proviral sequences38.
Progress has also been made in developing therapeutics for other human
diseases. An engineered I-CreI LHE was developed that could target and correct a defect
in the XPC1 gene of patients with Xeroderma pigmentosum 39,40. In a similar effort,
another engineered I-CreI LHE was developed to target the RAG1 gene in SCID 41,42. In
another example, an engineered I-CreI LHE was developed to correct a dystrophin gene
defect underlying Duchenne muscular dystrophy43.
Therapies built around genome editing tools are still in their infancy 25,44, and
there are a few main obstacles to their application. For example, many of these therapies
operate by genetically modifying a subset of the patient's (or a compatible donor's) cells
in culture, and transplanting them into the relevant tissue, where they multiply to
supplant the diseased cells; however, such a strategy is impossible in non-dividing cells.
Furthermore, genome editing with nucleases relies upon HDR for the insertion or
replacement of genetic material; however, HDR is downregulated in many terminally
differentiated cells, such as cardiomyocytes 45, or neurons46. Another complication arises
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from off-target DNA cleavage, which can cause unwanted genetic modifications. Take
for example the observation of Cre and φC31-mediated recombination of off-target
pseudo-recombination sites47,48, which has been shown to lead to deletions and
chromosomal re-arrangements in cultured cells49-51 and mice52. Additionally, DNA
damage has been observed at sites of ZF recombinase (ZFR)-mediated recombination 53.
Some of these modifications may convert proto-oncogenes to oncogenes, and lead to
cancer, as was the case with one notable attempt to treat ADA-SCID with gene therapy
using a viral vector and recombinase27. However, protein engineering approaches
provide an opportunity to develop new tools for genome editing that are more selective,
robust, and reliable.

1.2

Tools for Genome Editing
As a result of the many promises of the field of genetic engineering and gene

therapy presented above, a great deal of interest has been poured into developing tools
to advance the field of genome editing1,2,54-58. These tools are typically engineered
variants of enzymes that effect site-specific cleavage, such as recombinases, integrases,
HEs, or restriction endonucleases (REs). These engineered enzymes may also be
coupled to proteins whose native function requires sequence-specific recognition of
DNA, such as ZFs or TALEs. Each of these engineered enzymes has its own strengths
and failings, leading to the great diversity of genome editing tools – potential or proven
(e.g. TALENs, and CRISPRs). However, due to the caveats described above, none of
these tools have proven themselves sufficiently reliable in a clinical or therapeutic
context. Efforts to develop a robust therapeutic genome editing tool benefit from
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concurrent development of a variety of tools, each with unique characteristics. The
following sections describe those tools that are currently under development, and which
may yet provide a robust therapeutic genome editing tool.

1.2.1 Recombinases/Integrases
Recombinases (also known as integrases) are a class of enzymes responsible for
integration and excision of viral genomes, activation of developmental genes and
transposition of mobile genetic elements (MGEs) 59. Identification of recombinase
minimal nucleotide target sequences has permitted their use in metabolic and genetic
engineering, and synthetic biology. In this capacity, recombinases have been used to
create gene knock-outs60-62. Their high site-specificity also makes them useful for
targeted integration and excision of transgenic elements and selectable markers63-66.

1.2.2 Restriction Endonucleases
Recombinant type II REs are instrumental to molecular biology; both for their
usefulness in molecular cloning, and because of their high-fidelity and straightforward
reaction conditions, requiring only Mg2+ as a cofactor67. REs were initially discovered
during investigations of viral restriction, when it was observed that viral DNA was
eliminated from a bacterial cell68. Further investigation revealed that REs were targeting
specific 4-8 bp palindromic DNA sequences and methylation states to eliminate non-self
DNA. Indeed, REs are highly sequence-specific, as evidenced by intolerance to
substitutions in their target. For example, plasmid pAT153 has 12 EcoRV sites that differ
from the cognate target sequence by a single nucleotide, and the best of these was
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cleaved 6 orders of magnitude less efficiently (kcat/Km) than the cognate target69. Further,
a typical type II RE binds its cognate target with nano- to picomolar affinity, but against
a non-cognate target, affinity is only in the μM range70.
One consequence of such high sequence specificity is the difficulty of making
altered specificity type II RE mutants. Attempts to generate novel specificities in type II
REs by substituting amino acids used in base-specific interactions proved futile, and
tended to lead to reduced activity without significantly changing specificity71-73. This
outcome was explained by the role to which REs have evolved. REs must retain high
specificity against a single target, and so have redundant means of recognition,
conferred by an extensive network of intramolecular contacts and bound waters 74-78.
Furthermore, crystal structures provide only ground-state depictions of the enzymesubstrate (ES) complex, and gross amino acid substitutions often leave functional groups
at the wrong distance or orientation. However, some facile specificity changes have
been identified, but they required at least a pair of amino acid substitutions, one for each
nucleobase in the basepair79.
Despite being highly sequence-specific, most REs are fundamentally unsuitable
for genome editing. A given RE would be expected to cleave every 4 h bp, where h is the
length of the cognate site. Consequently, widespread cleavage would be expected in a
genomic context. For example, the human genome has ca. 50,000-13,000,000 sites of 84 bp, respectively. However, the type IIS RE FokI has proven invaluable to genome
editing efforts in that it has a non-specific ND that has been conjugated to DBDs to
generate chimeric nucleases, described in greater detail below (see §1.2.3 and 1.2.4).
Additionally, type V REs are a more recently discovered family of REs, and are
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uniquely suited to genome editing. Type V REs are components of the CRISPR/Cas
restriction system, which uses sequence complementarity to guide RNAs to target DNA
cleavage, and is the topic of the next section.

1.2.2.1 CRISPR/Cas9
First – and unknowingly – observed in 1987 during sequencing of the E. coli iap
gene80, it wasn't until 2005 that CRISPRs were recognised for what they were; a
bacterial defence system81-83. With further investigation, the full process was eludicated84,
85

. Foreign DNA sequences are incorporated into a CRISPR locus for later recognition.

These sequences are then transcribed as crRNAs, or “guide RNAs”, which are ssRNAs
that are bound by proteins expressed from CRISPR associated (cas) genes to cleave
foreign DNA complementary to the crRNA. Further study of CRISPR function revealed
that in type II CRISPR immune systems cleavage of DNA targeted by the crRNA could
be effected by a single gene product, Cas9 86. Cas9 binds another RNA, tracrRNA, which
itself binds a complementary region of the crRNA in order to recruit crRNAs to Cas9.
By merging the crRNA and tracrRNA into a single chimeric guide RNA, or sgRNA,
cleavage could be accomplished by a single RNA-enzyme pair 87. The direct method of
targeting through complementary basepairing and the simplicity of a two component
sgRNA-Cas9 system lended itself to genome editing approaches. Since the year 2013,
papers have been published demonstrating genome editing with the CRISPR/Cas9 in
human cells, zebrafish embryos, and bacteria88.

1.2.2.2 FokI Nuclease Domain is Useful for Genome Editing
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FokI is a modular type IIS RE, comprised of a site-specific N-terminal DBD and
non-specific C-terminal ND that is functional as a dimer 89,90. Although REs are generally
unsuitable for genome editing for the reasons discussed above, the FokI ND alone
provides an alternate strategy for targeting a specific genetic locus. FokI can be attached
to a pair of DBDs, each flanking a chosen target site to confer endonuclease function
against that site. DBDs that have been successfully used include ZFs and TAL effectors,
which are described in further detail below.

1.2.3 Zinc-finger Nucleases
Motivated by failed attempts at re-engineering REs, Chandrasegaran et al. took
the nonspecific ND from FokI and combined it with a ubiquitous DNA recognition
domain, ZF protein, as the DBD 91. Fusions of these domains functioned as endonuclease
with a target sequence defined by the ZF-DBD. The variety of ZFs, each recognising a
distinct trinucleotide gave promise to the approach 92. Indeed, several ZFs could be
appended to the FokI ND to make ZF arrays (ZFAs) 93. Each ZFA can be designed to
target a sequence of 9-12 bps, meaning that a complete FokI dimer recruited by a pair of
ZFAs can target a site defined by 18-24 bp. This extent of sequence recognition provides
a potential means to target a single site in a genomic context. However, the trinucleotide
recognition by the ZF proteins proved less stringent than their successor, TALE proteins.

1.2.4 TAL Effector Nucleases
The modular approach to defining a target site used for ZFEs was the inspiration
for another class of engineered nucleases, based upon TAL effectors 94. Identified from
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Xanthomonas bacteria95, TALEs are proteins comprised of repeating peptides that differ
by only two residues, known as the repeat variable diresidue (RVD) 96. These RVDs each
define a single nucleobase in the TALE recognition site, based upon the identity of the
two amino acids in the variable di-residue. Joined with the FokI ND, these TALE
nucleases provide a straightforward method of targeting any DNA sequence.

1.2.5 Homing Endonucleases
HEs are derived from a class of MGE that defy the laws of mendelian
inheritance. Discovered in 1970, HEs are unidirectionally inherited, owing to their
unique method of transmission97. HEs are responsible for catalysing a DSB in a naïve
allele, and co-opting DNA DSB repair pathways to integrate its host intron in a process
termed 'homing' (Figure 1.2)98. Since their discovery, HEs have been found in all three
domains of life99, and in different genetic contexts, within group I or group II introns 100,
as self-splicing inteins101-103, and as free-standing genes104.
Evolution of HEs has been guided by two somewhat contradictory forces. On the
one hand, the process of homing requires that HEs be highly site-specific such that they
insert reliably into the naïve allele, which is often a functionally critical gene 105, without
causing deleterious mutations. On the other hand, their continued propagation requires
that they be able to target homologous genes in (i.e. “jump” to) other species98. Indeed,
experimental determinations of HE target specificity have found that they bind long
targets (12-40 nts), and are thus highly site specific, yet tend to tolerate individual
substitutions106,107. The ability to bind long target sites in a site-specific (if not fully
sequence specific manner), and use DNA repair to alter a single genetic locus makes
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binding &
cleavage

HDR & insertion

Figure 1.2. Endonuclease homing is a process which relies upon precise
cleavage and repair, and is responsible for propagation of its MGE. Homing
is the process by which lateral transfer of a MGE (orange) from one allele
(turqoise) to another (magenta) is facilitated by the endonuclease which it
encodes. Once the endonuclease is expressed, it binds specifically to its homing
site (red) a sequence near the intended MGE insertion-site, and typically induces
a DSB in a naïve allele. When the MGE harbouring allele is used as a template
during HDR of the nuclease induced DSB, the MGE becomes incorporated into
the repaired strand, separating the homing site across the MGE and preventing
further DSBs.
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HEs a promising platform for the development of tools for genome editing.
All HEs currently identified fall into one of six families that are named after the
consensus amino acid sequence that defines the family. The six families are HNH, HisCys, PD-(D/E)xK, EDxHD, LAGLIDADG, and GIY-YIG 1. Although each of these
families share the above-mentioned characteristics of HEs, only two of these families
have been exploited for genome editing applications, LHEs and GIY-YIG HEs.

1.2.6 LAGLIDADG Family Homing Endonucleases
LHEs (also known as meganucleases) were the first family of HEs to be
identified, and since their discovery in 1970 they have provided a system to understand
MGEs108. This long history of investigation has produced a wealth of information about
LHE structure and mechanism, including 37 crystal structures to date. LHEs consist of
two LAGLIDADG domains that are either subunits of a dimer, or domains of a
monomer, that bind the enzyme's 16-26 bp cognate target (Figure 1.3) 109,110. The single
active site of LHEs is formed at the interface between pseudo-symmetric LAGLIDADG
domains, and is responsible for cleavage of both DNA strands. It is still unclear if LHEs
as a family require two or more divalent metal ions to effect catalysis, as examples of
both exist in the literature111,112.

1.2.7 Engineered LHEs for Genome Editing
LHEs provide a promising platform for genome editing. Their relatively small
size facilitates expression in the host organism, and extensive structural characterisation
facilitates rational design and targeted mutagenesis.
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Figure 1.3. I-OnuI LHE has a pseudosymmetric dimer of two structurally
similar domains. The structure of I-OnuI, like other LHEs, has a striking 2fold rotational axis. These domains are nonidentical, and each imposes its own
distinct substrate sequence preference.
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Furthermore, their two-domain pseudo-symmetric structure and growing number of
identified family members supports an intuitive mode of developing LHEs with altered
target site preferences via domain swapping. These characteristics combined have
allowed a repertoire of engineered LHEs with an extensive array of target site
preferences to emerge.
Efforts to engineer LHEs with altered target site preference fall into two broad
categories: mutagenesis-based approaches, and domain swapping approaches.
Mutagenesis-based approaches use directed evolution, rational design or computer
assisted design to identify amino acids of importance for binding or catalysis and
substitute one or more of these amino acids to effect a change in specificity. Domain
swapping approaches seek to first define independent functional domains of a
multidomain enzyme. These domains can then be recombined with functional domains
of other enzymes to produce a chimaera with a new, combined function.
In one example of the mutagenesis-based approach, the LHE I-OnuI was
engineered using directed evolution to preferentially target the human MAO B gene 4.
The MAO B gene has been implicated in the development of Parkinson's disease, and
MAO B itself is a therapeutic target. Within the MAO B gene there is a sequence that
differs from the native I-OnuI target sequence at only 5 base-pairs. The engineered
LHEs were generated by saturating mutagenesis of amino acid positions identified from
crystal structures to be in contact with those nucleobases that differed between the
native and MAO B target site, and selected over several rounds of directed evolution.
Ultimately, an engineered I-OnuI variant named I-OnuI E2 was developed that showed
an ~2.5-fold preference for the MAO B target over the native target site. This engineered

18
LHE was later incorporated into a chimaeric fusion with the ND of I-TevI to create a
dual-cutting endonuclease that presented a high frequency of site-specific gene
disruption in mammalian cell culture, without the need for end processing enzymes such
as Trex2113.
In an example of the domain swapping approach, the pseudosymmetry of LHEs
was capitalised on to generate an engineered HE named E-DreI 114,115. The “left” and
“right” domains of E-DreI were derived from two distinct members of the LHE family,
I-DmoI, and I-CreI. The N-terminal domain of I-DmoI and a monomer of I-CreI were
computationally combined, and amino acid substitutions were identified that optimised
the interdomain interface. In this way, the authors generated a chimaeric HE that
targeted a combined target site with an enzymatic efficiency on par with the parent
enzymes. Building on the success of E-DreI, 30 chimaeric LHEs were generated, of
which 14 displayed catalytic activity116.

1.2.8 GIY-YIG Homing Endonucleases: I-TevI
GIY-YIG HEs possess traits consistent with the prototypical GIY-YIG HE ITevI. I-TevI has an N-terminal GIY-YIG ND and a C-terminal helix-turn-helix (HTH)
DBD tethered by a flexible linker region (Figure 1.4A) 5, making I-TevI inherently
modular. A crystal structure of the C-terminal DBD with substrate, coupled with affinity
assays reveals that the DBD is responsible for most of the enzyme's binding affinity and
sequence recognition117,118. Functional characterisations have identified the N-terminal
ND as being responsible for cleavage 118, where it acts as a monomer to target sites based
upon both distance from the DBD and its own limited sequence specificity119. Cleavage
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A

B
TATCAACGCTCAGTAGATGTTTTCTTGGGTCTACCGTTTAATATTGCGTCA

Figure 1.4. Structure of I-TevI HE and its cognate target site convey
corresponding modularity. The structure of I-TevI (panel A) is composed of an
N-terminal ND (green, from PDB 1MK0), connected via a flexible linker to a Cterminal DBD (both in blue, from PDB 1IJ3). A portion of the I-TevI linker
region did not form a single ordered structure in the cocrystal, and is thus shown
diagramatically as a dotted grey line. Similarly, the cognate homing site (panel B)
can be divided into the cleavage motif (green), which is connected by a spacer to
the I-TevI binding site (both in blue).
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is effected in two sequential nicking reactions, where the bottom strand is nicked first in
a metal independent reaction, prior to the Mg2+-dependent nicking of the top strand119.
The I-TevI ND recognises a five-basepair cognate cleavage motif, 5' – CAACG – 3'.
Further investigation of the I-TevI ND cleavage profile revealed that it recognises the
more general cleavage motif, 5' – CNNNG – 3'120, equivalent to ~6 bits of information.
There is no clear pattern for cleavage of the 64 possible triplets (NNNs). Although some
NNNs are not cleaved, promiscuity abounds, and cleavage efficiency spans three orders
of magnitude113. The lack of direct correlation between NNN sequence and cleavage
efficiency indicates that indirect readout is likely playing a role in cleavage motif
recognition.
Investigation of I-TevI is hampered by the inherent toxicity of this enzyme to E.
coli cells121, which precludes traditional overexpression and purification techniques. For
this reason, studies of the I-TevI ND have been carried out using fusions of the ND with
other DBDs6 – analogous to FokI-based nucleases – or by extrapolating from
experiments done using a close relative of I-TevI, I-BmoI122.
The structural and functional modularity of I-TevI is evident in its modular target
site (Figure 1.4B)123, which is consistent with the view that the ND alone is responsible
for catalysis and is a contributor to cleavage motif sequence recognition. Although the
low binding affinity and dynamic nature of its mechanism 118 make the I-TevI ND less
accessible to characterisation by techniques that rely upon stable interactions (e.g.
crosslinking, STD-NMR, FRET, SPR, x-ray crystallography, or ITC), important residues
have been identified by mutagenesis. R27118, H40123, and E75124 have all been identified
as important catalytic residues, as I-TevI R27A or E75A were unable to effect DSBs,
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and H40Y had reduced activity. The function of these and other residues have also been
predicted by homology, using GIY-YIG NDs that exist in a variety of enzymes,
including I-BmoI, UvrC, Eco29kI, and Hpy188I (see below, Figure 3.5). Although
indirect methods have fostered a greater understanding of the I-TevI ND, the knowledge
required for re-engineering is currently incomplete.
As alluded to above, the I-TevI ND domain and its associated specificity can be
ported to other DBDs. This ND has been successfully paired with Zinc fingers 6,
TALEs125, 126, and LHEs6, 113. The value of such portability has already been demonstrated
by the extensive use of the FokI ND, described above. In the case of a combined I-TevI
and LHE chimaera (MegaTev), the combined cleavage activities and specificities of
these two enzymes together has been demonstrated to efficiently effect target gene
disruption113. Furthermore, the chimaeric MegaTev is not as toxic to E. coli as I-TevI,
and can be overexpressed and purified113. For these reasons, I used a fusion of the I-TevI
ND to a catalytically inactive variant of the LHE I-OnuI – where it functions as a DBD
– to generate the results described in this thesis.
The I-TevI ND possesses a number of characteristics that make it a potentially
useful component of genome editing tools. As mentioned above, the ND is active as a
monomer, which simplifies engineering constraints, and it has its own sequence
specificity, which reduces off-target cleavage. However, the use of this ND in genome
editing is restricted by its limited specificity, driving the need for I-TevI ND variants
with altered sequence specificity. This is made challenging by the lack of information
about the exact source of its cleavage specificity. Further, rational design is made
impossible by the lack of a co-crystal of the holo-enzyme, complete with substrate, thus
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directed evolution approaches are indicated.

1.3

Towards Engineering and Understanding the I-TevI ND

1.3.1 Hypothesis & Objectives
As described above, the I-TevI ND is highly sequence tolerant, likely stemming
from the use of indirect readout to recognise and cleave the 5' – CNNNG – 3' cleavage
motif. Understanding the mechanism by which readout is conveyed by I-TevI will
facilitate engineering of this portable ND. Thus, my null hypothesis is that readout of the
cleavage motif is not conveyed by residues of the ND, and that altering these residues
will not alter the cleavage profile of the I-TevI ND.

To test this hypothesis I pursued several research objectives:
Objective 1) Create a library of I-TevI ND mutants using random mutagenesis.
Objective 2) Use a directed evolution approach to selectively identify mutants that
are active on cleavage motifs that the wild-type I-TevI ND is not.
Objective 3) Identify which individual mutations or combinations thereof are
responsible for conferring said cleavage activity.
Objective 4) Overexpress, purify, and kinetically characterise a mutant MegaTev
with a new cleavage activity to determine its cleavage profile.

1.3.2 Scope & Relevance
My goal in this thesis was to identify mutations, and thus amino acid
substitutions of the I-TevI ND that alter its cleavage profile. I expect that the positions of
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these substitutions correspond to those that convey indirect readout of the cleavage
motif. By identifying amino acids that are putatively involved in conveying indirect
readout I hope to provide a means to better understand and potentially engineer I-TevI
NDs with a cleavage profiles that are orthogonal to that of the wild-type ND. Such NDs
could contribute to the development of a therapeutic genome editing tool.
The following chapter (Chapter 2) details the methods I used to carry out my
experimental objectives. Chapter 3 recounts the results of my selections, the mutants I
identified and their characterisation in vivo. Further, it described the in vitro
characterisation of the I-TevI ND triple mutant T3, which was revealed to have a
significantly relaxed cleavage specificity. Chapter 4 discusses the implications of the
mutations that I have identified with respect to previously identified mutations, and
presents the experiments that are now possible, and that I intend to carry out in
pursuance of my PhD. Finally, supplementary figures and tables present the results of
individual in vivo and in vitro assays, and specify the bacterial strains, plasmids, and
primers used to complete this work.
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Chapter 2

METHODS

All bacterial strains, plasmids, and oligonucleotide primers are listed in
supplementary Tables S.1, S.2, and S.3, respectively. All restriction enzymes were
acquired from NEB. Unless stated otherwise, small molecule reagents were acquired
from EMD.

2.1

Construction of Mutagenised I-TevI Libraries
I-TevI ND mutant libraries were generated using Mutazyme II (Agilent), a mix

of DNA polymerases for error prone PCR. Primers DE-840 and DE-1912 were used to
select the region to be mutagenised. 0.2 ng of the I-TevI ND was then mutagenised
throughout amino acids 10 – 95 under manufacturer-defined conditions for 30 PCR
cycles. Mutagenesis was repeated as before for another 30 cycles in a fresh reaction to
further increase the extend of mutagenesis before end-point PCR with Taq DNA
polymerase (NEB) was used to amplify the mutant ND sequences. A truncated I-TevI
linker region (residues 96-169) was amplified using end-point PCR with Taq and
primers DE-1424 and DE-1045, and then combined with the I-TevI ND mutant library
using splicing by overlap extension (SOEing) PCR with Phusion DNA polymerase
(Thermo Scientific) and primers DE-840 and DE-1045. The ND mutant library with
wild-type linker was digested with NcoI-HF and BamHI-HF and ligated using T4 DNA
ligase (NEB) into the PciI and BamHI sites of an I-OnuI E1 E22Q with hexahistidine
tag encoding plasmid, pACYCOnuE1E22Q(+H). Negative ligation controls were
conducted by omitting insert in a parallel ligation set up. Complexity of library was
determined based upon difference between colony count on ligation plate, and colony
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count on the negative ligation control. In the final construct, the library of chimaeric
MegaTevs with mutant NDs, was downstream of a T7 promoter/lac operator and a
ribosome binding site, and upstream-adjacent to a sequence encoding residues 4-307 of
I-OnuI E1 E22Q with a C-terminal hexahistidine tag.

2.2

Directed Evolution and Selection of Variants
Electrocompetent cells for directed evolution were prepared from E. coli strain

BW25141(λDE3) transformed with a pTox plasmid as described previously6. Batches of
electrocompetent cells were tested for lack of retention of the toxic plasmid by
transforming them with 10 ng pACYCDuet-1; batches of cells that displayed survival
greater than 0.1% under selective conditions (expression of the toxic protein, Ccdb)
were discarded. Typically, 50 μL of electrocompetent cells were transformed with 10 ng
of plasmid harbouring the I-TevI ND mutant library, and immediately diluted with 500
μL of SOC media for incubation at 37°C with shaking (280 RPM) for an amount of time
that depended on the round of selection underway. For the first round of selection,
cultures were incubated at 37°C for 6 h, while subsequent rounds were incubated for 1
h. 100 μL was diluted and plated as described below for in vivo survival assays. Another
200 μL was removed and diluted into two separate 5 mL aliquots of lysogeny broth (LB)
media: a “non-selective” media with chloramphenicol (25 μg/mL) alone, and a selective
media that also contained arabinose (10 mM). The diluted cultures were incubated at
30°C with shaking (280 RPM) for 18 h before being harvested by centrifugation and
their plasmids isolated using a plasmid miniprep kit (Bio Basic) for subsequent rounds
of selection.
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After two rounds of selection, those populations of mutant NDs that showed a
measureable increase in survival were PCR amplified with primers DE-840 and DE1045. The amplified DNA was treated with DpnI (NEB) to destroy any remaining round
2 plasmids, digested with NcoI-HF and BamHI-HF, and religated back into
pACYCDuet-1(PciI).
Round 4 survivors were sampled by picking five colonies from the
corresponding selective plates, and incubating them overnight in 5 mL LB media with
chloramphenicol (25 μg/mL) at 37°C, for subsequent plasmid isolation with a plasmid
miniprep kit.

2.3

in vivo Survival Assays
Electrocompetent cells harbouring pTox plasmids were generated as described in

the previous section, and were typically transformed with 50 ng of plasmid harbouring a
MegaTev with a mutant ND, and immediately diluted with 500 μL of SOC media for
incubation at 37°C for 1 h. Cultures were diluted 1/1, 1/10, 1/100, 1/1000 and 1/10000,
and 100 μL of diluted culture was plated on selective (chloramphenicol [25 μg/ml] and
arabinose [10 mM]) and non-selective (chloramphenicol [25 μg/ml]) LB media, and
incubated for 20 h at 37°C, and colonies counted. Data quality was improved by
discarding plates that did not meet the following criteria: colonies were only counted on
those plates that had >10 colonies (preferrably hundreds), or >0.1 % survival, whichever
was greater.

2.4

Construction of I-TevI Nuclease Domain Mutants
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Construction of I-TevI NDs that were not identified by sampling round 4
survivors was typically achieved by SOEing together fragments of previously identified
I-TevI ND mutants using Phusion DNA polymerase. To generate K26R, primers DE-840
and DE-1912 were used to amplify the ND of K26R Q158R from amino acids 1 to 95,
the wild-type linker region of I-TevI was amplified using primers DE-1045 and DE1424, and these two regions were joined using SOEing PCR as above for library
construction. Similarly, K26R T95S Q158R was made by combining the ND from K26R
T95S and the linker from Q158R. To generate K26S mutants, a pair of complementary
primers with single basepair mismatches to the wild-type I-TevI ND sequence installed a
K26S mutation. These primers were used in combination with primers DE-840 and DE1045 to construct each of the K26S mutants. A similar strategy was used to restore T95S
to T95 by amplifying the I-TevI ND with primers DE-840 and DE-2167, and combining
it with the linker sequence as above in order to generate the single mutants C39R, and
I86V.

2.5

Purification of Chimaeric MegaTevs

2.5.1 Overexpression of Chimeric MegaTevs in E. coli
Plasmids harbouring MegaTevs comprised of either a wild-type I-TevI ND or
the T3 ND were transformed into ER2566 E. coli cells (NEB), plated on LB media with
chloramphenicol (25 μg/mL), and incubated for 18 h at 37°C. A single colony per plate
was picked and used to inoculate a 20-mL LB culture (with 25 μg/mL chloramphenicol),
which was incubated at 37°C for 4-6 h before being diluted into 1 L LB culture (with 25
μg/mL chloramphenicol) and grown to OD600 = 0.8. The culture was then chilled on ice
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for 30 min, and 1 mL of 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) was added
to induce enzyme expression, before being incubated for a further 13 h at 15°C. The
cells were then harvested from the culture (now at OD 600 of 1.1-1.4) by centrifugation
(4000 ×g, 10 min), and the pellet collected and stored at -80°C for 16-24 h.

2.5.2 Chromatographic Purification of Chimaeric MegsTevs
The cell pellet was resuspended into 35 mL of binding buffer (20 mM Tris·HCl
[pH 8.0], 500 mM NaCl, 5% (v/v) glycerol, 10 mM imidazole) containing a protease
inhibitor mix (1/20th of a cOmplete™ protease inhibitor pellet [Roche, added as a
suspension of pellet in ddiH2O], per gram of cell pellet). Cells were then sonicated
(power 5, 50% duty cycle, pulsed mode, 5 × 20 pulses), and subjected to centrifugation
(20,000×g, 15 min) to separate the cell pellet from the soluble fraction, which was
removed and applied to a His-Bind column (Amersham). The column was then loaded
with a procession of buffers: ~45 mL of binding buffer, 15 mL of wash buffer (binding
buffer with 50 mM imidazole), and 5 mL of elution buffer (binding buffer with 300 mM
imidazole). The final 5 mL of eluate was dialysed (10,000 Da molecular weight cutoff
(MWCO) [Spectra/Por]) against 500 mL storage buffer (20 mM Tris·HCl [pH 8.0], 500
mM NaCl, 5% (v/v) glycerol, 1 mM dithiothreitol [DTT]) for 6 h at 4°C, before the
buffer was replaced, and dialysis continued for a further 12 h. In the case of the
MegaTev with a wild-type ND, aliquots and frozen at -80°C; these aliquots were
typically active for over a month when stored in this fashion. In the case of MegaTev
T3, the dialysed stock was kept at 4°C and used within a week.
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2.5.3 Determining MegaTev Quality and Quantity
All MegaTev purifications were followed by electrophoretic separation to
determine the purity of the aliquots before the concentration of MegaTev is quantified.
The concentration of MegaTevs in solution was determined by measuring the UV
absorbance of the solution at 280 nm (A280) and comparing it to the predicted extinction
coefficient (ε280) of the chimaeric MegaTev (67380 M−1∙cm−1). Predicted ε280 values were
calculated
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concentration was determined using the Beer-Lambert-Bouguer law127-129 (eqn 2.1; c is
the molarity, b is the pathlength [in cm]). It was assumed that the only significant
protein component in solution was MegaTev, on the basis of the SDS‒PAGE results
(Figure 3.7, below).

c = A280 / ( b·ε280 )

2.6

(2.1)

Barcode Assays and Kinetic Characterisation of Chimaeric MegaTevs
Barcode assay substrates were prepared by using pTox as template with a pair of

flanking primers equidistant from the cleavage motif (see supplementary Table S.3), in
end-point PCR. Substrates of 2200, 1900, 1600, or 1320 bp were made, and combined
into a single reaction. Substrates contained a 42 bp MegaTev target site comprised of a 5
bp cleavage motif, a 15 bp spacer from the I-TevI native target, and a 22 bp I-OnuI E1
target sequence from the human MAO B gene. The cleavage motif was placed such that
substrates would be cleaved in half to create two equally-sized products. Unreactive pre-
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mixtures were prepared on ice, and were comprised of 5 nM of each substrate, 250 nM
enzyme, and cleavage buffer (50 mM Tris·HCl pH 8.0, 100 mM NaCl, 1 mM DTT, 5%
glycerol). An aliquot of pre-mixture was removed immediately prior to starting the
reaction by adding 2 mM MgCl2, and incubating at 5°C for 30 min. Aliquots were
removed from the reaction mixture at 1, 2, 4, 10, and 30 min time-points (although for
practical purposes some aliquots were removed at 11 or 13 min instead of 10 min), and
quenched by the introduction of ethylenediaminetetraacetic acid (EDTA) and sodium
dodecylsulphate (SDS) (final concentrations of 83 mM, and 8.3%, respectively). Timepoints were resolved using agarose gel electrophoresis in TBE (100 mM Tris base, 100
mM boric acid, 2 mM EDTA [pH 8.0]) and spot densitometry was used to measure the
quantity of substrate remaining in the reaction, and the quantity of product formed. The
intensity of the corresponding substrate and product bands at each time-point are
summed, and normalised to the to the intensity of the substrate band at t = 0 (forcing
mass balance). The fraction of substrate remaining (fS) is then simply the ratio of the
normalised substrate band intensity to the initial intensity. Triplicate values were plotted
as fractions of substrate remaining at each time-point, and fit by non-linear regression to
a first-order decay curve (eqn 2.2, where fS is the fraction of remaining substrate, m1 and
m2 correct for a non-zero baseline or non-unity starting condition, respectively, m3 is the
kapp in reciprocal minutes, and t is the amount of time passed, in minutes). The apparent
first-order rate constant of decay (kapp) was normalised to kapp for the native cleavage
motif decay curve, and reported as relative kapp.

-m3t

fS = m1 + m2

(2.2)

31

2.7

Sequencing of MegaTev T3 Cleavage Products
Barcode assay substrates harbouring position 1 substitutions or the native

cleavage motif were digested with MegaTev T3 for 1 h at 37°C, substrates were isolated
from enzyme using a PCR cleanup kit (Bio Basic), and submitted for Sanger sequencing
with one of two flanking primers to obtain the sequence of the top strand (DE-410) and
bottom strand (DE-411).

32
Chapter 3
3.1

RESULTS

Mutagenesis, Genetic Selection, and Isolation of I-TevI Nuclease Domain
Mutants
My first research objective was to create a library of I-TevI ND mutants, with the

goal of isolating mutants with activity on cleavage motifs that are poor substrates for the
wild-type enzyme. To accomplish this objective, I first generated a library of I-TevI ND
mutants using an end point PCR technique that makes use of a mix of engineered DNA
polymerases that ensure an equal proportion of each mutation (e.g. A→C, G, or T).
I wanted to ensure that the library was of sufficient complexity to contain all
possible single amino acid substitutions at every position of the ND (20 amino acid
possibilities for each of 86 positions from 10-95, or 1720 single amino acid substitutions
in total). The complexity of the initial library was assessed in two ways: by the number
of successful transformants made with the library, and by the number and variety of
mutations found therein. E. coli BW25141(λDE3) were transformed with the MegaTev
ND mutant library and a subset were plated on LB media with chloramphenicol (25
μg/mL). After an 18 h incubation at 37°C, colonies arising from this subset of the full
culture were counted, and their number extrapolated to the full culture volume. Based
upon the number of colony forming units, the library was estimated to contain
approximately 70,000 cfu. Six of these colonies (LIB-1-LIB-6) were chosen at random,
grown overnight, and harvested to isolate their pENDO plasmids, which were sequenced
(Figure 3.1). One of the sequenced plasmids appeared to have undergone an
insertion/deletion reaction (LIB-4), and as a result, ~90% of its sequence had been
frameshifted; this sequence was excluded from further analyses. The other sequences
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Figure 3.1
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Figure 3.1. PCR with Mutazyme II Consistently Mutates the I-TevI Nuclease
Domain. Sequences of six clones from the the mutagenised nuclease domain library
(LIB-1 – LIB-6) are shown above, amino acid sequences on the left, and nucleotide
sequences on the right. In each of the six NDs there was a single, double, or triple
amino acid substitution. An indel in LIB-4 has resulted in a frameshift mutation that
has affected almost all of the amino acid sequence.
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were each revealed to have 1-4 amino acid substitutions, either transversions or
transitions, as summarised in Table 3.1 and 3.2.
A ratio of transversions and transitions as close to 2:1, but certainly greater than
1:1 was considered important because there are twice as many codons available through
transversions, and thus a greater set of possible mutations at a particular amino acid
position. The extent of mutagenesis observed in this sampling of the library yielded a
ratio of transversions to transitions of 1.5:1.
With a sufficiently complex library of I-TevI ND mutants in hand, my next
objective was to identify mutants that were active on cleavage motifs that the wild-type
ND is not. This objective was accomplished using a directed-evolution approach, in the
context of the MegaTev chimaeric nuclease. The library of randomly mutagenised I-TevI
NDs was fused via a partial I-TevI linker to a catalytically inactive I-OnuI E1 E22Q and
subjected to multiple rounds of selection and enrichment using a bacterial 2-plasmid
assay, delineated in Figure 3.2. This assay facilitated rapid phenotypic screening of a
library in a stringent, selective system with an easily controlled selective pressure in the
form of a double stranded plasmid DNA-substrate (pTox). pTox harbours a toxic gene
(ccdb, encoding the topoisomerase-inhibiting peptide, Ccdb), which is under arabinosemediated metabolic control (using the araBAD promoter). In this system, cleavage of
the target site linearises pTox, which is then degraded by the E. coli RecBCD complex,
allowing growth of cells with an active endonuclease. This selection is bacteriostatic,
not bacteriocidal, because the CcdB toxin inhibits DNA gyrase. Thus, even very limited
cleavage of pTox was sufficient to overcome the selective challenge. Since the
selections were done with a library of ND mutants under direct competition,
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Table 3.1. Survey of Observed
Nucleotide and Amino Acid Substitutions
Nucleotide
Amino Acid
# (%)
# (%)
Substitutions
Substitutions
Transitions
6 (0.4)
Missense
10 (2.35)
Transversions

9 (0.9)

Nonsense

2 (0.47)

Total

15 (1.5)

Total

12 (2.82)

Indels

1 (N/A*)

*Percent calculations did not include the sequence with an indel

Table 3.2. Survey of mutation rates in sample sequences.
Final

Initial

T

T

C

A

G

-

3

4

1

C

-

Identity
Transition

-

A

2

-

2

G

1

2

-

Transversion
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Figure 3.2. Bacterial two-plasmid selection discriminates between sufficiently
or insufficiently active I-TevI cleavage domains. Plasmids encoding the mutant
enzymes are transformed into E. coli harbouring a second plasmid encoding the
toxic gene ccdB under the arabinose-inducible BAD promoter, and a putative
endonuclease target site. If the target site is cleaved, the plasmid encoding the toxic
gene is rapidly degraded, and similar growth is observed in the presence and
absence of arabinose; if, however, the target site is intact, negligible growth is
observed in the presence of arabinose. By comparing the relative growth under
selective (+ara) vs. non-selective (-ara) conditions, % survival was determined.
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alleviating the bacteriostatic effect granted a critical selective advantage over nonreplicating or slowly replicating competitors. This approach was chosen because the
strongest survivors would be enriched and would dominate the population.
I expected that the mutations present in my library would be more likely to
broaden the cleavage profile of the I-TevI ND, rather than fully eliminate activity
against the native 5' – CAACG – 3' cleavage motif. Thus, if the library did not retain any
residual activity against the native cleavage motif, then it would have indicated that the
level of mutagenesis was too high, and had led to complete attenuation of ND activity.
Survival assays testing the library against the native cleavage motif revealed that the
library was able to survive (Table 3.3), albeit at a reduced level compared to the wildtype ND, which has previously conferred 100% survival.
Confident that I had a library which contained active I-TevI ND mutants, I chose
16 substrates that have been shown previously to be highly cleavage resistant to
cleavage by the wild-type I-TevI ND113 from the set of all 64 NNNs as the first priority
for extending the versatility of the I-TevI ND through a broadened cleavage profile. I
anticipated that mutations which resulted in cleavage of a poor substrate were likely to
directly influence nuclease activity, rather than result from indirect effects such as
increased protein stability or expression. The initial library was screened against all 16
poor substrates one by one (R1, Figure 3.3). Each screen required an independent
transformation of the library into competent cells harbouring an individual substrate. For
R1 only, freshly transformed cells were incubated in SOC media at 37°C for 6 h, before
selection proceeded for 18 h at 30°C. This generated 16 populations of enriched I-TevI
ND mutants.
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Initial Library
Survival Rate vs
CAACG (n=2, %)

17, 6

Table 3.3. Summary of initial library and R4 population survival rates against selected
substrates and specific mutations derived from R4.
Mutants Identified
wild-type
Survival Rate R4 Survival R4 Survival Rate vs
(n=3, %)
Rate (%)
CAACG (n=2, %)
Mutant
# of Observations
Q158R

1

4

Selected
Against

K26R Q158R

5

R4
Population

T95S

143, 64

113, 109

5

16

36

Q158R

1.6 ± 0.8

nil.*

86, 87

AAG

CCC

61

A

B

13.5 ± 6.1

1

GAA

C39R T95S

3

C

C39R I86V T95S

3

1

T95S

2

I86V T95S

K26R T95S

84, 81

107, 133

55, 87

2

20

29

37

T95S

nil.*

nil.*

nil.*

1

GCC

GGA

TGG

K26R T95S

D

E

F

*values of survival rate did not exceed background survival of negative controls (0.1%)
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A

B

Survival rate (%)

C

D

E

F

Figure 3.3. Mutant populations of I-TevI cleavage domains confer survival
against toxic plasmids harbouring CNNNG cleavage motifs with cleavage
resistant triplets. After a round of selection on the library (R1), the population of
survivors against each substrate was isolated, and subjected to a second round of
selection (R2). Those populations (A-F) that confer a measurable improvement in
survival over wild-type (WT), were recloned and subjected to two additional
rounds of selection (R3 & R4).
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In order to further enrich the mutants that cleaved poor substrates, the resulting
16 populations were each subjected to another round of selection against their respective
substrates (R2, Figure 3.3). For this and all further rounds of selection, selection was
made more stringent by incubating freshly transformed cells for only 1 h, rather than 6
h. The survival rate of each population after round 2 was compared to survival of the
wild-type I-TevI ND against the same substrate (e.g. survival rate of population A on 5'
– CAAGG – 3', compared to survival conferred by the wild-type enzyme against 5' –
CAAGG – 3'). Only those populations that showed any observable improvement in
survival over the wild-type I-TevI ND (wt, Figure 3.3) in R2 were pursued further.
Improvements in survival compared to the wild-type enzyme were often very clear,
since the wild-type did not survive to any extent. In these cases, survival greater than
0.1% (i.e. greater than background survival observed with an inactive ND) was
sufficient to merit further rounds of selection. In those situations where the wild-type
enzyme did confer survival to some extent, survival equal to, or greater than the wildtype was deemed sufficient. Such a lenient margin of success was chosen because
mutation is expected to reduce activity in general. Thus populations that were
indistinguishable from the wild-type enzyme in terms of activity would be expected to
also contain individual mutants that were more active than wild-type.
The populations I obtained in R2 could have been the result of mutations outside
of the I-TevI ND (e.g. chance mutations to promoter leading to increased expression of
endonuclease). I wanted to ensure that only mutations to I-TevI were maintained, and so
I recloned the open reading frames (ORFs) containing the I-TevI ND and partial linker
from each population into fresh background vector prior to further rounds of genetic
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selection.
After four rounds of selection (R4), six populations (A-F) were identified that
showed a marked improvement in survival, ranging from 4-fold for population C, to
>370-fold for population F, as summarized in Table 3.3. I wanted to assess to what
extent these populations had diverged from the initial library, and the wild-type I-TevI
ND. Namely, I wanted to know whether or not my directed evolution approach had
selected enzymes that preferred the cleavage motif they were selected against (e.g.5' –
CAAGG – 3' for population A) over the native cleavage motif (5' – CAACG – 3').
Unfortunately, bacterial 2-plasmid assays of R4 populations against the native cleavage
motif revealed that the native cleavage motif was still preferred by each of these
populations.
Although the R4 populations preferred the native cleavage motif, they displayed
substantial improvements in survival over the wild-type I-TevI ND against poor
substrates. Thus I wanted to know what mutations were present in these populations that
might confer said survival. Five colonies were chosen from plates of survivors on
selective media from each of the six populations (A-F), and their MegaTev ORFs
sequenced to identify their mutations. The number of each mutant genotype observed in
each population are tabulated in Table 3.3. One surprising mutation I observed (Q158R)
was outside of the mutagenised ND region of I-TevI, and instead was found in the
partial I-TevI linker. Otherwise, all mutations were observed within the I-TevI ND
region. Importantly, none of the MegaTev ORFs sequenced contained the wild-type ITevI ND and partial linker.
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3.2

in vivo Characterisation of I-TevI Nuclease Domain Mutants
Having isolated several mutant I-TevI NDs, I was interested in understanding

how – and critically if – each amino acid substitution is affecting the ND cleavage
profile. To determine the effect of individual mutations, mutant I-TevI NDs were made
containing single or double mutants from amino acid substitutions identified from the
genetic selections. The ability of each of these substitutions to confer survival in a
survival assay was determined in triplicate, and is summarised as a heatmap of average
survival values in Figure 3.4, and a table of values in supplementary Table S.4.
Because survival is an indirect measurement of cleavage activity, I was
concerned that the in vivo survival I had observed might be caused by a mechanism
independent of cleavage. If substrate pTox plasmids did not obviate survival in the
presence of a catalytically inactive I-TevI ND, then some cleavage independent
mechanism of survival could be providing the results I observed. To confirm that the
results I was observing required a catalytically active ND, triplicate negative control
survival assays were conducted using each substrate and a chimaeric MegaTev with a
catalytically inactive R27A ND mutant; no survival greater than 0.1 % was observed.
Each individual amino acid substitution conferred improvement in survival
against cleavage-resistant substrates, which was generally enhanced when substitutions
were combined. For example the K26R mutant displays an ~31% survival rate against 5'
– CAAGG – 3'. Similarly, the Q158R mutant displays an ~53% survival rate against 5' –
CAAGG – 3'. Combined, the K26R Q158R mutant displays an ~86% survival rate
against 5' – CAAGG – 3', and is an example of a combination of mutations that led to an
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K26R T95S Q158R (T3)
K26S C39R T95S
C39R I86V T95S
I86V T95S
C39R T95S
C39R I86V
K26R Q158R
K26S C39R
K26R T95S
K26S T95S
Q158R
T95S
I86V
C39R
K26R
K26S
wild-type

Figure 3.4
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Figure 3.4. I-TevI ND T3 cleavage specificity is a combined effect of individual
mutations. Individual mutations that were identified by survival assay screening
were introduced into the I-TevI ND individually, or in combination, and their ability
to confer survival in a 2-plasmid assay was assessed in triplicate. pTox plasmids
harbouring the native cleavage motif, or one of 16 cleavage-resistant substrates,
differing in their NNN triplet, were used in survival assays as described in the text.
Values below 1% are marked with an asterisk.
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additive effect on survival. The same combination of mutations resulted in an ~ 23%
survival rate against 5' – CCAGG – 3', despite the observation that K26R has no impact
on survival against that substrate individually, and Q158R has only an ~1.5% survival
rate against 5' – CCAGG – 3'. The observation that Q158R and K26R together have a
greater survival rate against 5' – CCAGG – 3' is an example of a combination of
mutations that led to a cooperative effect on survival. Through a combination of additive
and cooperative effects, the triple mutant K26R T95S Q158R (T3) conferred the highest
survival rates against the broadest range of substrates tested.
Perhaps most promising was the ~100% survival conferred by T3 against a C1T
substitution in the cleavage motif. C1 of the cleavage motif has previously been shown
to be necessary for cleavage by the wild-type I-TevI ND. This result is the first
indication that mutants could be developed that cleave targets which differ at this
position of the cleavage motif.
Since these amino acid substitutions conferred enhanced survival under the
conditions described above, they represented putative functionally important residues.
Thus I expected that exchange of these residues with those found at analogous positions
within another GIY-YIG ND would bestow some of that ND's substrate preference.
Comparison of the I-TevI ORF with the related GIY-YIG HE I-BmoI, revealed that all
of the positions identified here were also positions of non-identity with I-BmoI, as
depicted in Figure 3.5. Thus, mutants were made that possessed amino acids consistent
with I-BmoI at these positions (K26S, C39R, & T95S). Disappointingly, I-TevI ND
mutants with these amino acid substitutions fared no better than wild-type against the
substrate containing a CCCCG cleavage motif, which contains an NNN triplet identical
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to the native I-BmoI cleavage motif GCCCG.

3.3

in vitro Barcode Assays
The triple mutant T3 was able to confer survival against a broad range of

substrates that the wild-type I-TevI ND could not. However, these results could have
been explained by other convoluting variables, such as decreased toxicity, increased in
vivo stability, increased catalytic activity, other modes of pTox deactivation, or a
combination of these effects; thus, in vitro characterisation was indicated.
The barcode assay developed by Monnat et al. for rapidly determining HE target
sites22 can be used to assess cleavage of four unique substrates in a single, competitive,
in vitro, kinetic assay, and is described schematically in Figure 3.6. This assay can be
used to quantitatively determine kinetic constants for individual substrates relative to the
native 5' – CAACG – 3' cleavage motif. For these assays, two I-TevI chimaeras were
overexpressed and purified as described above. The I-TevI chimaeras were comprised of
the first 169 amino acids of I-TevI, comprising the ND and a partial linker region from
either wild-type or T3, and a C-terminal, catalytically inactive I-OnuI E1 E22Q.
Purifications resulted in active enzyme of sufficient purity to proceed with in vitro
assays (Figure 3.7). Although enzyme activity was observed to decline over time (weeks
for the wild-type ND and days for the T3 ND), it was assumed that this did not affect the
relative cleavage of each substrate.
The I-TevI ND T3 was assayed in vitro against assorted substrates that were
predicted to be poor substrates of the wild-type I-TevI ND, and those substrates that
differed from a poor substrate by a single basepair (Figure 3.8, supplementary Table S.5,
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*

*

*

*

Figure 3.5. Protein sequence alignment of I-TevI and I-BmoI NDs reveals
key sequence dispairities between these orthologs that correspond to
mutations identified in selections. Sequences of I-TevI and I-BmoI NDs were
aligned using Clustal ω. Residues that were identified in selections are marked
with red asterisks. Additional GIY-YIG domains from Eco29KI, Hpy188I, and
UvrC are also aligned for reference.
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Figure 3.6. 'Bar code' in vitro cleavage assay facilitates quantitative
assessment of mutant I-TevI cleavage domain activity. Substrates of varying
length (panel A), each bisected by a unique cleavage motif are combined into a
single competitive reaction with a Tev-Onu mutant (panel B), started by addition
of Mg2+, halted by sequestration of Mg2+ by EDTA, and visualised on an agarose
gel (represented by panel C). The varied length substrates facilitate measuring
relative cleavage of each substrate. An example of an agarose gel is shown (panel
D) from which band densities are measured and used to calculate disappearance
of substrate over time (measured as [St]/[S0] = fS or fraction of substrate
remaining), which are plotted and fit with a first-order decay curve to determine
the rate of decay (panel E).
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and supplementary Figure S.1). Altogether, assays were conducted on 34 distinct
substrates, using a 50-fold excess of endonuclease to ensure that substrates were
saturated with bound endonuclease, and thus only the rate of cleavage was being
measured. Furthermore, assays were conducted at 5°C to ensure that initial cleavage
rates were slow enough to be measured. Each assay contained a substrate with the native
5' – CAACG – 3' cleavage motif, which was used as an internal standard for the rate of
enzyme catalysed substrate decay (represented by kapp). All enzyme activities are
reported relative to cleavage of the native cleavage motif standard (relative kapp).
Although there is no consistent ratio between the wild-type and T3 ND rates of cleavage
for any particular substrate, the T3 ND is generally more promiscuous (Figure 3.8).
The in vitro results were generally consistent with the in vivo results; increases in
survival conferred by the T3 ND were associated with increased catalytic activity.
However, there are cases where a small increase in survival rate was associated with a
large increase in cleavage activity. For example, survival on the 5' – CGCTG – 3'
cleavage motif by the T3 ND increased to 13% from 0% for the wild-type. This
relatively modest increase in survival rate was associated with a nearly 4-fold increase
in relative kapp, from 0.18 for the wild-type ND to 0.73 for the T3 ND. Conversely, there
are also cases where a small increase in cleavage efficiency was associated with a large
increase in survival. For example, survival on the 5' – CAAGG – 3' cleavage motif
increased from 1.6% for the wild-type ND to 54% for the T3 ND. This pronounced
increase in survival rate was associated with an only 1.3-fold increase in relative kapp,
from 0.38 for the wild-type ND to 0.51 for the T3 ND. Although cases such as these do
exist, they represent the minority. In the majority of cases, a large increase in survival
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Figure 3.7. I-TevI chimaeras were isolated from E. coli ER2566 cells at
>95% purity. The results of a typical purification is displayed by the
polyacrylamide gel, shown above. Uninduced cells express an undetectable
amount of the I-TevI chimaera (Un), but after induction with IPTG, I-TevI
chimaera can be observed after lysis and centrifugation of the cells in both the
insoluble cell pellet (CP) and supernatant (Sn). The I-TevI chimaera is retained
by a His-Bind column, and is not observed in the flow-through (FT) or after the
first wash with binding buffer (B). Wash buffer (W) does remove some of the ITevI chimaera, but renders the elution (E, or diluted 1/5 as E 1/5) almost
completely free of non-specifically bound proteins. Complete removal of Ni2+
from the column with EDTA reveals that very little I-TevI chimaera remains on
the column (F), and that the purification consistently yields a protein of the
predicted molecular weight (54.6 kDa), when compared to prior purification (+)
and known molecular weight standards (L).
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Figure 3.8
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Figure 3.8. Kinetic assays reveal that the T3 mutant has a distinct cleavage
profile. Incubation of barcode assay substrates with a chimaeric fusion comprised
of either the wild-type I-TevI ND or the T3 ND, resulted in a first-order decay of
said substrates. The apparent first order kinetic constant for this decay (kapp) was
determined for each substrate, and normalised to the kapp-value for the native
target site substrate present in each assay. These relative kapp-values are graphed
for both the wild-type ND and the T3 mutant. The substrates used differed from
the native target site by either the NNN triplet, or at position 1 of the cleavage
motif. Further, they are either highly cleavage-resistant substrates used in vivo
(marked with a red asterisk; e.g. the TGG triplet), or else related to such a
substrate by a single nucleotide substitution (e.g. the triplets AGG, or TCG).
Values that exceed the dashed line at 0.5 roughly correspond to those for which
survival was observed in vivo.
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rate conferred by the T3 ND was accompanied by a correspondingly large increase in
relative kapp value, and vice versa.
Because barcode assays are inherently competitive, any differences between the
substrates could be contributing to their differing rates of cleavage. Thus I was
concerned that the length of the substrates may have influenced my results. Although the
exact mechanism by which the chimaeric MegaTev constructs bind their substrate is
unknown, one possible mechanism involves a slow DNA binding step, followed by a
rapid sliding of the MegaTev along the DNA helix to find its target sequence, as is the
case for the RE EcoRV130. In such a situation, a longer substrate would be expected to
have an accelerated DNA binding step, ultimately leading to faster cleavage.
To determine if the length of the substrate had an impact on cleavage efficiency,
the native I-TevI cleavage motif (5'–CAACG–3') substrates were synthesized in each of
the four possible lengths (2200, 1900, 1600, and 1320 bp). These substrates were mixed,
and cleavage monitored, as shown in Figure 3.9A. It was determined that substrate
length had a negligible effect on cleavage rate.
Another consideration for any competitive assay must be the effect of residual
substrates on the rate of cleavage of their competitors. This may be observed as a
cooperative effect, where the cleavage of each substrate is enhanced or attenuated by the
presence of its competitors. To determine if there was any impact of cooperative effects
between multiple enzyme-substrate pairs on cleavage efficiency, a set of substrates were
synthesized that contained a highly cleavage-resistant cleavage-motif 5' – AAACA – 3'
(1A5A) in three lengths (2200, 1600, and 1320 bp) and a native cleavage motif substrate
5' – CAACG – 3' (1C5G) of the remaining length (1900 bp). As shown in Figure 3.9B,
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Figure 3.9. Cleavage assays were unaffected by the length of substrate used, or
the concentration of other substrates in the reaction. Cleavage assays were
conducted under the same conditions as similar bar code assays used previously.
Despite being of different lengths 2.2, 1.9, 1.6 or 1.32 kbp, substrates containing
the native cleavage motif were not cleaved at rates more disparate than standard
error (A). Further, no effect of uncleaved substrate (C1A G5A [1A5A]) on
cleavage of the native cleavage motif (1C5G) was observed (B).
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only the native cleavage motif showed any significant decay over the assay period, and
this decay was aptly fit by a first-order decay curve (R 2 = 0.98). Despite a large quantity
of residual substrate being present during the full extent of the assay, the decay of the
remaining substrate was not observably perturbed. Although some decay was seen, this
was likely an artifact, considering that none of the other cleavage resistant substrates
were cleaved. The artifact in question is most common when all substrates are present;
each substrate causes an increase in background intensity for the substrate immediately
above it on the gel image. Thus as the substrate containing the native cleavage motif
decays into products, the background intensity of the first cleavage-resistant substrate
declines as well, leading to an apparent drop in intensity over time. Regardless, such
artifacts were not expected to have any effect on determination of kapp because the
correction factors m1 and m2 (described more fully in § 2.6) compensate for this.
Collectively, these experiments show that cleavage is non-cooperative and unaffected by
substrate length.

3.4

Cleavage Site Sequencing
Although promiscuity by I-TevI has already been observed for positions 2, 3, and

4 of the cleavage motif, a position 1 C of the 5' – CAACG – 3' cleavage motif was
previously determined to be necessary for efficient target site cleavage. Thus, the
observation that the T3 triple mutant aptly cleaves C1T in vivo, and all position 1
substitutions in vitro was surprising. This promiscuity could be explained by cleavage of
a secondary target-site that is triggered by the absence of C1. To explore this possibility,
the products of cleavage reactions with T3 and each of these substrates were sequenced
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using the Sanger method. These sequencing data revealed that the cleavage site has not
changed for any of the position 1 substitutions (Figure 3.10). The cleavage motif is
nicked on the bottom strand between positions 2 and 3 of the cleavage motif (Figure
3.10 for.), and on the top strand between positions 4 and 5 (Figure 3.10 rev.). It is
important to note that the Taq DNA polymerase used for Sanger sequencing affixes a
single adenosine to the 3' end of a nascent strand which is apparent in the readouts from
the upstream primer as an additional 3' adenine, and on the readouts from the
downstream primer as a 5' thymine.
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Figure 3.10. The position of substrate nicking reactions of I-TevI T3 are
unaffected by subsitutions at position 1 of the cleavage motif. pTox plasmids
harbouring native cleavage motif (C1C [C, D]), or one of three position 1
substitutions (C1A [A, B], C1G [E, F], C1T [G, H]) were sequenced using
flanking primers: one upstream of the cleavage motif (for. [A, C, E, G]) and one
downstream (rev. [B, D, F, H], the reverse complement is shown). Sanger
sequencing readouts are shown with traces for adenine (green), cytosine (blue),
guanine (black), and thymine (red). The cleavage motif is given above the
corresponding region of the readout, with a chevron indicating the predicted
nicking position. A drop-off in fluorescence intensity is seen in each sanger
readout corresponding to the predicted nicking positions in all eight cases.
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Chapter 4

DISCUSSION & CONCLUSIONS

Altering the specificity of existing HEs is central to any effort to extend the
versatility of this genome editing platform; however, altering the specificity of HEs has
proven difficult. Typically, success is achieved by separating the HE into 'modules' that
retain their function when recombined with modules from other proteins. In the case of
I-TevI, the ND has been shown to be such a module, and has been ported to numerous
other DBDs; however, the native cleavage specificity of the I-TevI ND is limiting, and
thus installing new specificities are desired. In previous cases, new specificities were
developed through a relaxed specificity intermediate. Further, installing new
specificities is facilitated by a knowledge of which amino acids are responsible for
conveying substrate specificity and defining the cleavage profile. Thus identification of
amino acids in the I-TevI ND that result in relaxed specificity is a twofold success; in
addition to generating a relaxed specificity mutant, it provides indirect evidence of the
amino acids that convey specificity in the wild-type ND. My goal in this thesis has been
to determine if the I-TevI ND is responsible for controlling the cleavage motif cleavage
profile. I did this by testing the null hypothesis that mutagenesis of the I-TevI ND would
not alter the cleavage profile.

4.1

Directed Evolution of I-TevI Nuclease Domains
My first and second research objectives were the creation of a library of

mutagenised I-TevI ND from which I would try to identify I-TevI ND mutants that could
cleave substrates that the wild-type could not. In the preceding chapters, I described how
mutagenic PCR was used to generate a library of I-TevI ND mutants, from which NDs
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with altered specificities were selected over multiple rounds of directed evolution. Six
populations of mutant I-TevI NDs survived 4 rounds of selection on substrates AAG,
CCC, GAA, GCC, GGA, and TGG (population A-F, respectively). It was interesting that
in these 6 populations, all 12 individual mutants identified possessed either a T95S or a
Q158R mutation. This was the first indication that these mutations would prove
important for altering the I-TevI ND cleavage profile. Another notable mutation was the
K26R mutation, which is immediately adjacent to the catalytically critical R27, and was
the only mutant identified in combination with both Q158R and T95S, indicating a
potentially significant impact on catalysis when combined with both of these mutations.
However, the absence of K26R, C39R, or I86V mutations in isolation indicates that
these mutations may be less important for catalysis. Ultimately, the small sample size of
isolated mutants (5 per population), and the potential for a founder effect in the PCR
mutagenesis cast doubt on these assertions, and a more detailed study of these mutations
was needed; regardless, my first two objectives were complete.

4.2

Individual Mutations: Potential Impacts on Catalysis and Structure
My third objective was to identify individual I-TevI ND mutations or

combinations thereof that would confer survival against substrates that the wild-type ND
could not cleave. My intention was to identify the ND mutations that had the strongest
impact on survival, and thus were most likely to be of direct catalytic relevance. The
exact mechanism by which the mutations I identified alter specificity is unknown, and
was not directly attended to in this thesis; however, most of the mutations described
above are oriented towards the putative active site of the I-TevI ND (Figure 4.1),
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presenting a possibility for them to have a direct role in catalysis. Furthermore, some of
these mutations occur adjacent to residues with an established catalytic role.

4.2.1 Individual Mutations: K26R is Adjacent to Catalytically Critical R27
An R27A mutation in the I-TevI ND abolishes the second, top-strand, nicking
reaction and thus R27 likely has a direct role in cleavage of the top-strand
phosphodiester bond. Although the precise mechanism of I-TevI is not known, the
mechanism of other GIY-YIG NDs have been elucidated in greater detail. Hpy188I is a
RE from Helicobacter pylori, and contains a GIY-YIG ND. Crystallographic studies
have solved the structure of this enzyme with its substrate bound, in which R84
(analogous to R27 in I-TevI, Figure 3.5) is observed in a crystal structure orienting the
water molecule that makes a nucleophilic attack on the phosphodiester bond 131. UvrC, a
component of the DNA damage repair pathway also contains a GIY-YIG ND, in which
R39 (analogous to R27 in I-TevI, Figure 3.5) appears to be involved in charge balancing
of the pentavalent phosphate intermediate that forms following nucleophilic attack by
water132. Thus K26R may simply assist R27 by positioning the scissile phosphate
accordingly, or it may stabilise the pentavalent phosphate intermediate that accompanies
phosphodiester bond cleavage as in the mechanism of the HE I-PpoI 133, Eco29kI134, or
UvrC132. One intriguing possibility is that K26R is acting as a redundant catalytic
residue, that steps in to catalyse cleavage of substrates for which the orientation of R27
is sub-optimal due to perturbations of DNA backbone structure that accompany
alterations of DNA sequence (in this case, the cleavage motif). Such a possibility could
be tested by generating a K26R R27A mutant, and testing for in vitro cleavage or in vivo
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C39
I86

T95

H40
R27

K26

Figure 4.1. Mutations K26R, C39R, and T95S affect the I-TevI ND active site.
Key catalytic residues H40 and R27 are oriented towards the active site groove of
the I-TevI ND. K26, C39, and T95 are also oriented towards this groove, or could
adopt a conformation to do so.
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survival as described in this thesis.

4.2.2 Individual Mutations: C39R is Adjacent to Catalytically Important H40
H40 has been identified as being catalytically important: H40Y is structurally
stable, as evidenced by substrate bending studies, but is less able to effect catalysis.
Histidine residues typically contribute to catalysis by acting as a general base, stabilising
anionic intermediates via charge balancing or H-bonding, or by chelating metal atoms.
In the proposed mechanism of the GIY-YIG ND in Eco29kI, a histidine residue (which
does not coincide with H40 in sequence alignments with I-TevI) is responsible for
deprotonating one of the conserved tyrosine residues of the GIY-YIG sequence, which
in turn deprotonates a water molecule such that it can nucleophilically attack the scissile
phosphate to effect phosphodiester bond cleavage134. In the proposed mechanism of
Hpy188I, a histidine residue aids in coordinating the divalent metal ion responsible for
orienting the phosphodiester group such that nucleophilic attack by water ejects the 3'hydroxyl group of the downstream nucleotide131. Each of these roles could be
modulated, enhanced, or abolished by a nearby guanidinium group, as in the C39R
mutation.
It is worth noting that cysteine can act in a similar fashion to the histidine
residues in the examples above; however, given that this residue is not conserved across
GIY-YIG domains, and no C39A or similar mutations exist, it is currently difficult to
speculate about what catalytic role – if any – this residue could have. There also exists
the possibility that C39R has no direct catalytic impact at all. Consider that, as can be
seen in Figure 3.4, the C39R mutation has only a weak ability to confer survival. This
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weak influence on survival is in contrast to the strong influence on survival that a
substitution directly involved in catalysis would be expected to have (e.g. catalytically
dead R27A NDs confers no selective advantage over empty backbone vector, as
evidenced by the <0.1% survival observed for both). These observations may point to
another possible explanation. C39 is notable for being present as a cystine in the I-TevI
R27A ND crystal structure (PDB ID: 1LN0) 135, forming a disulfide bond to C39 of an
adjacent I-TevI ND. Although C39R has a relatively small impact on changing
specificity, it may reduce the sensitivity of the ND to oxidative stress or posttranslational modification, thus its role may be connected to in vivo stability moreso than
catalysis. It may be illuminating to measure or follow the expression of the MegaTev
chimaera with or without the C39R mutation using S 35 pulse-chase to determine levels
of expression in the cell and turnover.

4.2.3 T95S: Implications for the I-TevI Nuclease Domain C-Terminal Region
T95S contributed significantly to survival against a number of poor substrates
with NNN substitutions (GAA, TGG, GCC, GGA, and CCC) but not against any of the
poor substrates with position 1 substitutions (C1A, C1G, or C1T). This could indicate
the role of this amino acid in I-TevI. T95 is located at the border of the ND and the
linker region, a region of poorly defined structure and function, however its impact on
NNN triplet recognition suggests that this region is important for defining how this
triplet is recognised. Because the triplets seem to be read – in part – through indirect
readout (i.e. through the response of the DNA to structural perturbations rather than by
specific H-bonding patterns of the major-groove surface) the C-terminal region of the
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ND in which T95S is found may be responsible for positioning the substrate for readout,
or straining the substrate DNA to bring the catalytic residues and substrate into the
proper orientation (activated state) for catalysis. Such a difference might be borne out by
a thermodynamic study of the cleavage of substrates with varying NNN triplets by the ITevI wild-type and T3 ND to explore differences in ground-state substrate binding and
transition-state binding between these two NDs, and between cleavage resistant and
cleavage facile substrates.

4.2.4 Significance of Similarities of Mutations to I-BmoI Sequence
Some of the amino acid substitutions identified by the selections described
herein are already present in another GIY-YIG HE, I-BmoI, which has the native
cleavage motif 5' – GCCCG – 3'. Thus a set of mutations were installed in I-TevI to
emulate the sequence of I-BmoI at these positions, namely K26S, C39R, and T95S, to
see if such substitutions led to marked improvement of cleavage of substrates similar to
the I-BmoI cleavage motif, namely C1G (5' – GAACG – 3') or CCC (5' – CCCCG – 3').
Disappointingly, K26S and C39R did not impart any significant advantage, either alone
or with other mutations, against substrates similar to the I-BmoI native cleavage motif.
However, T95S was singularly responsible for improved survival against CCC, and
another K26 substitution, K26R, when combined with Q158R and T95S, conferred
survival against all position 1 substitutions, including C1G.

4.2.5 The Curious Case of Q158R
One of the mutations identified from selections was particularly surprising,
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namely Q158R. This mutation was not identified in any of the regions that were
intentionally mutagenised, and likely arose spontaneously during PCR amplification of
the linker region during library construction. Furthermore, Q158 is within a ZF DBD
that has not been thus far linked to the specificity or DNA-binding affinity of the
enzyme136, but rather to distance determination. The significant increase in survival
conferred by Q158R against both cleavage resistant NNN triplets and position 1
cleavage motif substitutions cannot easily be explained by altered cleavage distance
determination, especially in light of the cleavage motif sequencing results, which
indicate that in fact the cleavage site has not changed.
One possible reason for the impact of the Q158R mutation on survival may be
that it is acting as a suppressing mutation of sorts, and counteracting disturbances
created in the linker due to the fusion of residues 1-169 of I-TevI to I-OnuI E1 E22Q.
This mechanism of expanding the cleavage profile of I-TevI could be investigated by
including Q158R in chimaeric MegaTevs that have more of the native linker region
between the ND and I-OnuI E1 E22Q. If a MegaTev with a longer linker does not have a
broader cleavage specificity after inclusion of Q158R, then it would be unlikely that this
substitution suppresses the effect of fusions made only 11 aa downstream to the same
extent as fusions made as many as 37 aa downstream (as would be the case for fusions
with residues 1-201 of I-TevI)6. A more likely cause for this result in this case would be
that the substitution effects its change upstream instead, perhaps by influencing the
orientation of the linker, and through mechanical coupling, the orientation of the ND.

4.2.6 The Triple Mutant: K26R T95S Q158R (T3)
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The most promising individual mutations identified in survival assays were
K26R, T95S, and Q158R. Unsurprisingly, when these mutations were combined into a
single triple mutant, the result was an I-TevI ND and linker with a significantly
expanded survivability in survival assays. The creation of a triple ND mutant with
expanded survivability is not consistent with the null hypothesis that the I-TevI ND is
not responsible for the cleavage motif cleavage profile. However, since the survival
assays do not measure cleavage per se, it was not known whether or not these
substitutions were the result of a change in the catalytic activity and cleavage profile of
the ND. Thus these results were not necessarily inconsistent with the null hypothesis
either, and direct measurement of cleavage using in vitro assays was indicated.

4.3

Information Gleaned From in vitro Assays
My fourth research objective was to overexpress, purify and kinetically

characterise an I-TevI ND mutant to determine its cleavage profile. If the cleavage
profile has clearly changed in a manner consistent with the ND mutations assayed in
vivo, then indeed the ND is at least partly responsible for defining the cleavage motif
cleavage profile. As alluded to in the previous section, in vivo data obtained from
survival assays cannot be directly correlated with activity because of numerous
convoluting variables in a biological system. Indeed, tight regulation of HEs is required
to prevent detrimental effects to the host organism137,138, which are not necessarily
replicated in the bacterial 2-plasmid system. Thus survival may be conveyed through
reduced toxicity (e.g. reduced affinity/activity for some as-yet unknown site in a critical
component of the E. coli genome), increased in vivo stability leading to higher steady-
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state enzyme concentrations, or even through unanticipated downregulation of the
topoisomerase inhibitor used as selective pressure in these assays, similar to the
autoregulation of wild-type I-TevI, in which I-TevI binds and obscures a regulatory site,
but cannot cut it because of an absent cleavage motif137. Even if these results are due to a
catalytic effect, the data presented in sections 3.1 and 3.2 does not discriminate between
increased activity against all substrates (since there is an upper bound of ~100%
survival), or altered specificity through increased promiscuity. Furthermore, the in vivo
data provides only a coarse estimate of activity since the standard error for such an
experiment can be quite large. Thus, in vitro assays are indispensable for distilling the
enzymatic consequences from a whole-cell system; this kind of experiment has the
sensitivity to discriminate between increased activity against all substrates.
In general, it can be seen that the T3 ND cleaves the cleavage-resistant substrates
more efficiently than the wild-type ND, as measured by the first order rate constant that
describes the decay of each substrate over time. For some substrates assayed (e.g. GCA,
GTG, and GCT) there was a large disparity between the in vitro cleavage rates between
wild-type and T3 NDs, but relatively a relatively small enhancement of in vivo survival
rate by the T3 ND. Conversely, assay of some substrates (e.g. CCC, and AAG) revealed
a comparatively small disparity between in vitro cleavage rates, despite a large increase
in survival. Although this initially seemed to point to a conflict between the two data
sets, further examination revealed that the data is quite consistent with a threshold
effect: survival in vivo corresponded to a relative kapp value greater than or
approximately equal to 0.5.
While this correlation is somewhat crude and exceptions exist, it could be still be
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used as a rough measure of the extent of convoluting variables affecting in vivo data: if
the in vitro data suggest that there clearly should or should not be survival for a chosen
enzyme-substrate pairing, then conflicting in vivo data would indicate that variables
other than cleavage rate may need to be considered. That being said, further
characterisation to ensure this threshold effect is observed with other substrates in vitro
and in vivo would be necessary to give confidence to such a metric.
The NNN triplets presented in Figure 3.8 represent only half of all possible NNN
triplets. Thus one obvious step forward will be to determine the exact kinetic impact of
each of these mutations on cleavage of all 64 possible NNNs. Another consideration that
was not attended to in this thesis is the impact that these mutations may have on
cleavage of position 5 substitutions. Although the position 5 G of the I-TevI cleavage
motif, like the position 1 C has been previously demonstrated to be required for
cleavage, the mutations I've described above may provide the ability to relax this
requirement.

4.4

Future Directions
Although the results of the work described in this thesis are inherently

informative, they also form the foundation of the project that I will be undertaking
towards completion of my PhD thesis: a thermodynamic and kinetic investigation of the
underlying cause of the I-TevI cleavage profile. As mentioned in the introduction to this
thesis, there is no obvious pattern to the NNN triplets that I-TevI will cleave, and
indirect readout through the biophysical characteristics of the triplets is likely
responsible for the cryptic cleavage profile. By identifying I-TevI ND mutants that
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present an altered cleavage profile, I can begin identifying correlations between the
specific thermodynamic and kinetic characteristics of the mutants, and the ability to
cleave a particular NNN triplet. In the same spirit as Prof. Richard Feynman's famous
words, “If I can build it, then I understand it” my hope is that these correlations can be
used to reverse engineer I-TevI NDs with practically any desired cleavage profile.
Below are briefly described some of the projects I will be pursuing in my PhD, which
are derived from the results in this thesis.

4.4.1 Additional Directed Evolution of I-TevI Nuclease Domains
Although there was extensive redundancy in the mutations identified from my
genetic selections, a more thorough exploration of the surviving I-TevI ND mutants may
identify additional mutations that expand the I-TevI ND cleavage profile, diminish the
number of cleavage resistant substrates, and complement experiments designed to
elucidate the mechanism by which ND mutations expand the I-TevI cleavage profile.
In engineering an enzyme with a new substrate specificity, it can be useful to
first develop a more promiscuous enzyme capable of acting on both its original substrate
and the new substrate. This promiscuous enzyme can then be refined to act selectively
on the new substrate. I propose that the same approach could be applied to the I-TevI
ND. The T3 mutant has a more relaxed cleavage profile compared to wild-type, for the
set of substrates assayed thus far. An I-TevI ND mutant with an orthogonal cleavage
profile might be developed by further mutagensing the T3 mutant, and then conducting
rounds of selection in which cleavage of a chosen substrate is selected against, by
including the corresponding target site into the pEndo vector, which harbours the I-TevI
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ND mutant itself. Thus only mutants that cleave the target site in pTox, but not in pEndo
will be maintained in the population. Mutations identified by such a bi-functional
selection could not only inform on those amino acids that facilitate cleavage of cleavage
resistant substrates, but also reveal those amino acids that must be maintained in order to
facilitate cleavage of the target site included on pEndo.

4.4.2 Kinetic Investigations of the I-TevI Nuclease Domain Cleavage Profile
I-TevI has a two step mechanism in which the bottom strand is nicked prior to
cleavage. Studies with I-BmoI have indicated that the rate of each nicking reaction
varies depending on the chemical environment of the ND active site, namely the
divalent metal ion present139. I posit that the resistance of each NNN triplet to cleavage
is mediated by perturbing the active site chemical environment, and that this will
manifest as a reduction of the rate of one or both nicking reactions. Moreover, I propose
that the extent to which each nicking reaction is compromised may be correlated to the
nucleobases on the same strand as, and directly adjacent to, the scissile phosphate. This
information is hidden in measurements of overall cleavage (such as the barcode assay)
because overall cleavage would proceed at a rate defined only by the nicking reaction
that becomes the rate-limiting step. I further propose that the ND mutants that I have
identified will display an increase in the rate of one or both nicking reactions.
Collectively, I expect that the substrates that a particular mutant cleaves better than wildtype will be those substrates that compromise the same nicking reaction that the
mutation accelerates. In other words: the cleavage-resistant substrates impose a ratelimiting step that the mutations counterbalance, such that on the whole, the reaction
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proceeds efficiently.

4.4.3 Thermodynamic Investigations of the I-TevI Nuclease Domain Cleavage Profile
Even in the absence of direct observation, there is a great deal about the
mechanism of an enzyme that can be elucidated by examining the thermodynamics of its
function. The extent to which a particular kinetic constant varies with temperature can
be used to determine thermodynamic constants for that reaction, such as the individual
contributions of enthalpy and entropy changes to transition state stabilisation and ground
state destabilisation140,141. An enzyme that contorts its substrate might be expected to
strongly reduce the entropy of bound substrate, as it is gripped tightly and forced into an
unfavourable conformation. Such contortions would have to be compensated for by a
similarly strong reduction of enthalpy, typically effected using extensive hydrogen
bonding, close packing of hydrophobic surfaces, and geometrically optimal salt bridges.
As discussed in the introduction, indirect readout seemingly plays a part in the I-TevI
ND cleavage profile. Since indirect readout is in essence recognising the response of a
segment of DNA to strain, I propose that cleavage of the native I-TevI cleavage motif
will be accompanied by a large decrease in entropy. It stands to reason that indirect
readout cannot function properly if the required strain cannot be generated. Thus, I
propose that cleavage resistant substrates are as such because they are also resistant to
the contortions required for indirect readout, either because they are too stiff to be
contorted to a significant degree, or they are flexible and are able to contort their
structure without induction of significant strain. In either case, I expect that cleavage
resistance will manifest as a complete or partial mitigation of the large reduction of
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entropy anticipated for binding of the native target. Consequently, I propose that the ITevI ND mutants that effect cleavage of cleavage resistant substrates will display an
enhanced reduction of entropy upon substrate binding regardless of the substrate being
cleaved.

4.5

Conclusions
Efforts to re-engineer nucleases have made significant progress over the past

decade. However, these efforts have also proven challenging, and the goal of a fully
customiseable nuclease is still incomplete. This work represents the first time the
cleavage specificity towards the I-TevI cleavage motif has been altered. Furthermore,
since the I-TevI ND and partial linker are portable to other DBDs, this result is a step
towards improving the versatility of a genome editing system in which a DBD and an ITevI ND mutant are combined on the basis of their specificity to effect genome editing
at any chosen locus. Additional work will be required to further alter and hone the
specificity of these mutants, using both positive selection as described above, and an
additional negative selection, which eliminates ND mutants that cleave a particular
cleavage motif by – for instance – placing that cleavage motif in the ND mutant
expression plasmid. Perhaps more importantly, the mechanism by which the mutants
identified by genetic selection change the I-TevI cleavage profile is poorly understood
and requires further study.
Engineering successes and newly opened avenues of research aside, the question
remains: were the results of this thesis consistent with the null hypothesis or no? I
observed that the ND mutations K26R and T95S were able to expand survivability in
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vivo, especially when combined with Q158R. Importantly, Q158R was not able to
confer survival against some NNNs such as TGG without the assistance of K26R, and
especially T95S. However, it could be argued that the inclusion of Q158R undermines
the premise of the experiment. Q158R is not a ND mutation, and its influence on the
cleavage motif cleavage profile convolutes the influence of the true ND mutations. Yet,
the correlation between in vitro cleavage and in vivo survival strongly suggests that
pronounced survival against a substrate was the result of substrate cleavage. The single
mutant T95S was able to confer pronounced survival against an expanded set of
substrates, which in light of the correlation between survival and cleavage, indicates
that it did indeed relax the cleavage motif cleavage profile, in direct conflict with the
null hypothesis.
I think it is worth noting, however, that whatever contribution the T95S
mutation had on relaxing the I-TevI cleavage profile, it was greatly augmented by the
addition of Q158R. Further, T95S is at the extreme limit of the canonically defined ND
of I-TevI, and those mutations that were clearly within the ND proved far less capable of
conferring expanded survivability in vivo. Thus I propose a new hypothesis: The
cleavage motif cleavage profile is defined in part by residues within the I-TevI ND, and
in part by residues of the linker region, and that these residues work cooperatively.
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Appendix 1: Bacterial strains, plasmids and primers used for the development of
this thesis, and raw data underlying the results.
Below are found tables listing the all of the bacterial strains, plasmids, and
primers used to develop this thesis (Table S.1, S.2, and S.3, respectively). Also included
are tables quantifying the results of the numerous survival assays completed to generate
figure 3.4 (Table S.4). Finally, a table of data summarising the kapp-values (Table S.5)
and the plots with fitting data used to derive them (Figure S.1)
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E.coli – NEB5

Strains

F- λ- fhuA2 [lon] ompT lacZ::T7 gene 1 gal sulA11 Δ(mcrC-mrr)114::IS10
R(mcr-73::miniTn10-TetS)2 R(zgb-210::Tn10)(TetS) endA1 [dcm]
N.E.B.

F - , φ80d lacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk- ,
mk+), phoA, supE44, λ- , thi-1, gyrA96, relA1

Description

N.E.B.

Source

Supplemental Table S1: Bacterial strains used in this study

E.coli - ER2566

F- lacIq rrnBT14 DlacZWJ16 DphoBR580 hsdR514 DaraBADAH33 DrhaBADLD78
galU95 endABT333 uidA(DMluI)::pir+ recA1, λDE3 lysogen

Description

Novagen

Source

Ref [6]

E.coli - BW25141(λDE3)

Plasmids

orip15A, cm, pACYCDuet-1 with a PciI site substituted for the NcoI site

Ref [6]

Supplemental Table S2: Plasmids used in this study

pACYCDuet-1(PciI)

oripBR322, amp

oripBR322, amp
Promega
p11-lacY-wtx1, that contains a 42-bp hybrid I-TevI/I-OnuI E1 homing site
(td bases -27 to -8 fused to the I-OnuI E1 site) cloned into the XbaI and
SphI sites(DE1064/1065)
Ref [6]

p11-lacY-wtx1

pToxTO1.20

Similar to pToxTO20, with C1A and G5A substitution(DE1156/1157)

pSP72

pToxTO1.20 C1A/G5A

pACYCDuet-1(PciI), containing the I-OnuI E1 gene with a E22Q mutation
cloned into the BamHI and XhoI sites
Ref [6]

Ref [6]

pACYCOnuE1(E22Q)
(+H)

pTevN169-OnuE1(E22Q) pACYCOnuE1(E22Q)(+H), with residues 1-N169 of I-TevI (DE) cloned
(+H)
into the PciI and BamHI sites (+6xHis)
Ref [6]
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Supplemental Table S3: Oligonucleotides used in this study

Name

Sequence (5'-3')

Notes 1

DE410

GGAAGAAGTGGCTGATCTCAGC

Forward primer to generate all cycle-seq products for
target sites cloned into pTox

DE411

CAGACCGCTTCTGCGTTCTG

DE840

GCCG CCATGGGTAAAAGCGGAATTTATCAGATT

Reverse primer to generate all cycle-seq products for
target sites cloned into pTox
Forward primer for I-TevI cloning, NcoI site
underlined

DE1045

CGC GGATCCATTTCTGCATTTACTACAAG

Reverse primer for TevN169 cloning, BamHI site
underlined

DE1424

CGTTTGGTGATACATGTTCTACG

Reverse primer for I-TevI linker cloning.

DE1912

DE2184

CGTAGAACATGTATCACCAAACG
GGAAGTGCTAAAGATTTTGAATCGAGATGGAAGAGGCATTTT
AAAG
CTTTAAAATGCCTCTTCCATCTCGATTCAAAATCTTTAGCACT
CCC

DE2222

CCCAAACAGGTCGCTGAAATGC

DE2223

TGTCACGCTCGTCGTTTGGTATGGC

DE2224

ATGACGACCGTAGTGATGAATCTCTCC

DE2225

TCATGGTTATGGCAGCACTGC

DE2226

AAAAAAATCGAGATAACCGTTGGC

DE2227

CCGCGCCACATAGCAGAACTTTAAAAGTGC

DE2228

ATTGTCCATATTGCATCAGACATTGC

DE2229

ACTTCACCAGCGTTTCTGG

Reverse primer for generating the 1900 bp barcode
assay substrate from pTox templates.
Forward primer for generating the 1600 bp barcode
assay substrate from pTox or pKox templates.
Reverse primer for generating the 1600 bp barcode
assay substrate from pTox or pKox templates.
Forward primer for generating the 1300 bp barcode
assay substrate from pTox or pKox templates.
Forward primer for generating the 1300 bp barcode
assay substrate from pTox or pKox templates.

DE2230

AAATTAATAGGTTGTATTGATGTTGGACGAGTCG

Reverse primer for generating the 2200 bp native I-TevI
target barcode assay substrate from pKox templates.

DE2231

AAATTGCAGTTTCATTTGATGCTCG

DE2296

TGAGACACAACGTGGCTTTGTTGAATAAATCG

DE2297

TCCATGTTGGAATTTAATCGCGGCCTCG

DE2183

1 underlined nucleotides refer to restriction enzyme sites

Reverse primer for mutagenesis of the I-TevI nuclease
domain, PciI site is underlined
Forward primer for installation of K26S into top
strand.
Reverse primer for installation of K26S into bottom
strand.
Forward primer for generating the 2200 bp barcode
assay substrate from pTox or pKox templates.
Reverse primer for generating the 2200 bp barcode
assay substrate from pTox templates.
Forward primer for generating the 1900 bp barcode
assay substrate from pTox or pKox templates.

Reverse primer for generating the 1900 bp native I-TevI
target barcode assay substrate from pKox templates.
Reverse primer for generating the 1900 bp non-native ITevI target barcode assay substrate from pKox
templates.
Reverse primer for generating the 2200 bp non-native ITevI target barcode assay substrate from pKox
templates.
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C1G

C1A

ACG

GAG

AAG

CCC

CAG

CCA

GCT

GGG

GGA

GCC

TGG

GCA

GAA

GTG

TCG

AAC

Substrate

0.00±0.00

0.00±0.00

0.00±0.00

0.07±0.12

0.00±0.00

1.60±0.82

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

13.50±6.06

0.00±0.00

0.00±0.00

89.00±2.65

wt

8.30±4.12

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

75.00±36.59

4.53±2.27

1.50±0.26

0.00±0.00

0.20±0.00

0.00±0.00

5.90±4.28

0.37±0.06

1.50±1.22

0.00±0.00

53.33±9.29

0.00±0.00

0.00±0.00

95.67±13.05

1A(Q158R)

15.67±8.14

0.40±0.10

0.00±0.00

2.00±0.35

0.40±0.17

73.67±30.89

4.27±2.57

23.00±3.00

0.00±0.00

0.10±0.00

0.00±0.00

5.93±4.27

0.90±0.10

3.33±1.21

0.00±0.00

86.00±34.04

0.13±0.06

0.00±0.00

118.00±41.76

1B(K26R Q158R)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

6.47±5.20

42.33±26.01

0.00±0.00

0.00±0.00

0.10±0.00

0.00±0.00

23.50±18.30

43.00±28.05

18.23±14.65

0.00±0.00

23.33±4.51

0.00±0.00

0.00±0.00

131.67±33.65

2A(T95S)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

4.70±3.82

46.47±32.10

0.00±0.00

0.00±0.00

0.10±0.00

0.00±0.00

17.37±13.56

33.43±22.13

10.53±9.04

0.00±0.00

15.77±6.64

0.00±0.00

0.00±0.00

66.17±29.10

2B(I86V T95S)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

7.47±6.12

45.00±22.91

0.00±0.00

0.00±0.00

0.30±0.00

0.00±0.00

26.97±24.11

32.67±20.01

25.40±14.25

0.00±0.00

17.67±5.13

0.00±0.00

0.00±0.00

86.43±30.51

2C(C39R I86V
T95S)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

7.87±6.47

35.20±31.70

0.00±0.00

0.00±0.00

0.10±0.00

0.00±0.00

25.93±24.10

29.90±24.06

17.87±13.97

0.00±0.00

15.33±2.52

0.00±0.00

0.00±0.00

77.30±34.13

2D(K26R T95S)

2.43±2.57

0.00±0.00

0.00±0.00

2.43±3.09

0.00±0.00

4.43±3.49

74.33±16.56

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

5.73±1.10

58.33±28.43

29.33±12.70

0.00±0.00

42.67±6.43

0.00±0.00

0.00±0.00

100.17±37.52

2E(C39R T95S)
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C1T
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CAG

CCA

GCT

GGG

GGA

GCC

TGG

GCA

GAA

GTG

TCG

AAC

Substrate

4.13±0.68

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.08±0.13

2.50±1.83

1.86±0.22

0.00±0.00

7.87±7.06

0.00±0.00

0.00±0.00

104.00±30.64

2F(K26S T95S)

12.67±20.21

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.99±1.41

12.83±10.25

5.82±3.82

0.00±0.00

20.00±18.25

0.00±0.00

0.00±0.00

116.33±43.02

2G(K26S C39R
T95S)

26.33±9.07

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

31.33±18.77

0.00±0.00

0.00±0.00

64.30±6.55

0A(K26R)

14.27±7.75

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

27.67±11.24

0.00±0.00

0.00±0.00

92.33±11.02

0B(C39R)

4.60±2.56

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

20.67±10.79

0.00±0.00

0.00±0.00

88.60±26.38

0C(I86V)

14.27±13.13

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

17.33±10.41

0.00±0.00

0.00±0.00

72.50±35.57

0D(C39R I86V)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

73.33±22.05

0E(K26S)

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

0.00±0.00

118.33±43.19

0F(K26S C39R)

0.00±0.00

54.00±24.25

64.00±53.23

2.33±0.55

4.97±6.26

13.33±0.58

0.00±0.00

80.33±13.80

71.33±33.84

88.33±33.95

21.00±6.24

84.67±31.90

0.00±0.00

0.00±0.00

139.37±83.39

K26R T95S Q158R
(T3)

Table S.4. (Part 2 of 2) Survival Rates Determned from in vivo 2-Plasmid Surival Assay

CCC
0.00±0.00

24.67±21.94

0.00±0.00

3.07±2.16

AAG

4.93±2.78

0.00±0.00

0.00±0.00

107.33±51.52

0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00

0.00±0.00
0.00±0.00

0.00±0.00
0.00±0.00

0.80±0.44

0.00±0.00
0.00±0.00

ACG
C1A
0.00±0.00

GAG

C1T

C1G
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Table S.5. Apparent First-Order Rate Constants for
Substrate Decay by Chimaeric MegaTevs with wild-type or T3 NDs
kapp
kapp
Substrate
AAA
AAC
AAG
AAT

wild-type
0.73 + 0.08
1.00 + 0.11
0.38 + 0.04
1.07 + 0.14

T3
0.41 + 0.05
0.33 + 0.05
0.17 + 0.02
0.32 + 0.04

Substrate
AAC
CCG
GCG
TCG

wild-type
1.07 + 0.18
0.02 + 0.01
0.05 + 0.01
0.21 + 0.02

T3
0.29 + 0.04
0.07 + 0.01
0.10 + 0.01
0.23 + 0.03

AAC
CCC
GCC
TCC

0.74 + 0.07
0.27 + 0.02
0.26 + 0.03
0.58 + 0.06

0.85 + 0.09
0.41 + 0.03
0.69 + 0.06
0.72 + 0.07

AAC
CGG
GGG
TGG

0.63 + 0.06
0.032 + 0.004
0.12 + 0.01
0.18 + 0.01

0.15 + 0.04
0.02 + 0.02
0.11 + 0.03
0.13 + 0.02

AAC
CAG
GAG
TAG

0.74 + 0.06
0.14 + 0.01
0.16 + 0.01
0.29 + 0.01

0.63 + 0.07
0.11 + 0.01
0.18 + 0.01
0.37 + 0.03

AAC
CTG
GTG
TTG

0.51 + 0.05
0.08 + 0.01
0.15 + 0.01
0.32 + 0.02

0.40 + 0.05
0.25 + 0.04
0.17 + 0.02
0.26 + 0.03

AAC
ACG
AGG
ATG

1.00 + 0.07
0.27 + 0.02
0.38 + 0.03
0.48 + 0.07

0.85 + 0.09
0.41 + 0.03
0.69 + 0.06
0.72 + 0.07

AAC
CCT
GCT
TCT

0.63 + 0.04
0.28 + 0.01
0.11 + 0.00
0.21 + 0.01

0.11 + 0.01
0.083 + 0.005
0.078 + 0.005
0.10 + 0.01

AAC
CCA
GCA
TCA

0.90 + 0.09
0.12 + 0.02
0.26 + 0.03
0.60 + 0.06

0.53 + 0.06
0.08 + 0.00
0.27 + 0.02
0.45 + 0.05

C1A
C1C
C1G
C1T

0.15 + 0.02
0.78 + 0.05
0.10 + 0.01
0.10 + 0.01

0.05 + 0.01
0.16 + 0.02
0.08 + 0.01
0.10 + 0.01

AAC
CGA
GGA
TGA

0.57 + 0.04
0.041 + 0.002
0.072 + 0.003
0.20 + 0.01

0.35 + 0.06
0.05 + 0.01
0.22 + 0.02
0.32 + 0.04

2200
1900
1600
1320

0.75 + 0.07
0.77 + 0.08
0.67 + 0.08
0.63 + 0.06

n.d.*
n.d.*
n.d.*
n.d.*

*Not determined
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Figure S.1. Barcode assay kinetic data. MegaTevs with a wild-type ND (WT
[A, C, E, G, I, K, M, O, Q, S, U, W, X]) and MegaTevs with a triple mutant K26R
T95S Q158R (T3 [B, D, F, H, J, L, N, P, R, T, V]) were assayed against four
substrates of varying lengths (2200 [yellow ▲], 1900 [blue ▲], 1600 [green ▲],
and 1320 bp [red ▲]). Substrates harboured I-TevI cleavage motifs, one of which
was the native cleavage motif (5' – CAACG – 3'), and the others were comprised
of NNN triplet substitutions (5' – CNNNG – 3' [A-T]), position 1 substitutions (5'
– NAACG – 3' [U, V]), or control substrates. The controls involved either all
native cleavage motifs, one of each of four lengths (W), or a single native
cleavage motif (1C5G [X]) among cleavage resistant motifs (5' – AAACA – 3',
1A5A [X]). All assays were conducted at 5°C, with 250 nM enzyme, and 5 nm of
each substrate. The equation of fit is explained in detail in the text (see eqn. 2.2).
Note that the equation given below is superficially different; using the identities y
= fS, and x = t, the equations below become eqn 2.2.
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